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Introduction:  The O2 Gold magnetic device is a non-medicinal inhaler containing a magnetic 
coil that has been designed to improve cardio-respiratory function. Oxygen (O2) in the inhaled 
air passes through the magnetic coil in this breathing device and acquires a magnetic charge.  
Former studies (Ryan, 2007; Roberts, 2007) have reported improvements in peak power output 
and post-exercise recovery, supporting anecdotal reports of improved peak power output in 
world-class endurance athletes following regular use of this device. The mechanisms by which 
this improved peak power output may occur, are however unknown. 
 
Objectives:  The primary objectives of this study were to determine the effects of 28 days of 
regular use of the magnetic breathing device on the cardio-respiratory function of well-trained 
endurance athletes during an incremental exercise test to exhaustion. Secondary objectives 
included the determination of lung function and red blood cell status at rest, and maximal 
exercise performance and O2 uptake (VO2) as well as heart rate (HR) and blood pressure (BP) 
response to a maximal exercise test.  Finally the possible role of systemic concentrations of 
erythropoietin (EPO) and interleukin-3 (IL-3) as mediators of the beneficial effects of the 
magnetic breathing device on red blood cell status, was investigated.   
 
Study design and methods:  The study was designed as a double blind, placebo controlled, 
cross-over trial.  18 Healthy male participants volunteered from running and triathlon clubs in 
the greater Durban area. The participants were particularly suited to a set of inclusion criteria 
which included a specific age range (>18 and <45 years), were recreational or professional 
runners that were willing to maintain a training schedule of at least three times per week for the 
three months leading up to, and during the study period. The participants were required to use 
both the magnetic and placebo breathing devices, 30 times a day for 28 days each.  Each 
participant acted as their own control and the sequence of the trials was determined by the 
manufacturers of the pre-coded devices. At baseline and after active/placebo intervention, 
anthropometric characteristics and lung function were assessed and venous blood samples were 
collected for later determination of full blood count (FBC), serum EPO and plasma IL-3 
concentration. Metabolic and respiratory responses to an incremental exercise protocol were 
determined during an incremental maximal exercise test. Selected cardiovascular parameters 
including BP and HR were also measured before, during and for the first two minutes following 






Results:  Ten participants, aged between 27 and 40 (mean: 32.3±4.9 yr) with a mean stature 
(cm) of 175.8±7.7 reported compliance with all aspects of the study. Analysis of the physical 
characteristics, including mass, % body fat, resting HR and blood pressure in this sample (n=10), 
revealed no significant difference (p>0.05) between mean (±SD) at baseline and after placebo or 
active trials.  
 
Six participants (60%) recorded a statistically significant (p<0.05) improvement (vs. baseline) in 
forced vital capacity following the active and placebo trials. Maximal exercise test duration 
ranged between 8 to 17 minutes. Five participants (50%) recorded a statistically significant 
improvement (vs. placebo, p=0.02) in maximum treadmill workload and running time following 
the active trial.  
 
Six of the sample presented with RBC count increases in (vs. placebo) and five with an increase 
in Hb concentration (vs. placebo) following the active trial. The mean (±SD) increases in this 
subsample of positive responders were both significant (p=0.02; 0.047) and corresponded with 
increases in VO2 maximum in each of these individuals. However no significant differences 
(p>0.05) were obtained in the means (±SD) of the circulating concentration of the hormone EPO 
and the haematopoietic growth factor, IL-3, between active and placebo trials.  The association 
between pre-post change in serum EPO concentration and plasma IL-3 concentration and 
changes in RBC count were also  not significant (p>0.05).  
 
Mean (±SD) and range of recovery HR, both 60 and 120 seconds post-test, showed no 
statistically significant improvement (n=10, p>0.05). Upon analysis of individual results, four of 
the participants showed an improvement in 120 second post maximal exercise test HR recovery 
when using the active device. The mean (±SD) of the improvement in this subsample was 
statistically significant (p=0.03). Although mean (± SD) post-test diastolic BP was not 
significantly lower in the full sample (n=10), there was a significant drop in this parameter in 
five individual participants following the active trial (p<0.03).  
 
Conclusion:  Only 50% of this subsample presented with significantly improved performance 
during the treadmill running test and 40% with significantly improved Hb concentration, HR at 
120 seconds post exercise and post exercise DBP. 60% of the sample presented with a significant 
improvement in RBC, but this was not related to an associated increase in VO2 maximum. 
Serum IL-3 and plasma EPO concentrations do not appear to be the mechanisms by which the 




The possibility of the existence of responders and non-responders to this intervention and factors 
which influence this potential response, require further examination. Further studies examining 
the benefits of the magnetic breathing device, also need to consider the possibility of under-
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INTRODUCTION TO THE STUDY 
 
1.1  Background 
Magnetic therapy, the use of magnetic fields to treat a range of medical conditions, has in 
recent years accumulated a great following. It has been observed that magnetic fields have 
the ability to alter water solubility, enzyme activity, gene expression, ion transport, 
membrane permeability and mitochondrial function (George et al., 1996). It has also been 
shown that magnetic therapy is beneficial in arthritis and pain relief (Mizushima, 1975), and 
that it enhances neurological and endocrine function (Hong, 1987). 
 
The Therahaler® O2 Gold is a magnetic breathing device that was originally invented by 
Bryan Speight of the Royal Pharmaceutical Society of Great Britain in 1998 and is currently 
being marketed as the “O2 Gold” by a South African company,  Rexi Pharmaceuticals CC. A 
magnetic coil of strength 1500 or 3000 Gauss (G) is the active component of the inhaler and 
inspired air is drawn directly through it. The manufacturers currently recommend that it is 
used over a period of 4-8 weeks, with a minimum of 25-30 inhalations to be taken daily at 
any stage or interval period throughout the day. 
  
When air is inhaled through this device, it passes through a magnetic field at which point the 
inhaled oxygen (O2) is ionized and develops a magnetic charge. The magnetized O2 is then 
drawn into the lungs and onto the iron binding sites of the haemoglobin (Hb).  O2 transport 
to alveolar capillaries is thought to be accelerated and binding to Hb improved (Chater et al., 
2006; Roberts et al., 2008). The manufacturers claim that the magnetic charge is then 
imparted onto a number of different molecular and biological systems as the blood circulates 
through the body. 
 
The magnetic breathing device was first designed to assist with asthmatic patients’ 
integration into a normal, functional lifestyle.  Rexi Pharmaceuticals CC claims that the O2 
Gold is non-medicative and beneficial to athletes of all ages. These marketers of the O2 Gold 
magnetic inhaler also suggest that athletic performance may be enhanced by magnetic fields, 
possibly by accelerating cell membrane substrate transport systems, elevating enzyme  
activity and ATP production.  Further claims following magnetic induction and use of a 
2 
 
magnetic breathing device are an elevation in haematocrit (Hct) and Hb concentration 
(Chater et al., 2006), improvement in immune response (Jankovic et al., 1991), improved 
respiratory muscle function (Roberts, 2008), a lower resting heart rate (HR; Ryan, 2010), as 
well as post-exercise HR recovery (Ryan, 2007), collagen deposition (Zhang et al., 2000) 
leading to accelerated muscle repair (Zhang et al., 2000), and increased bone mineral density 
(Costantino et al., 2007). 
 
For athletes, international attention and the rise in popularity of sport has been partnered 
with a tremendous amount of pressure to excel and maintain high performance levels. This 
has led to many athletes opting for performance-enhancing substances which are often illegal 
and potentially detrimental to their long-term health (Krcik, 2001). The magnetic breathing 
device may serve as a viable substitute for illegal performance enhancers if it yields the 
results claimed by the former marketers, Magnetic Air Health Products, and Rexi 
Pharmaceuticals. 
 
In the initial two unpublished pilot studies examining the effects of regular use of the 
Therahaler® O2 Gold on athletic performance over a four week-period, first described by 
Roberts (2004), heart rate recovery in 14 triathletes after completing a 15 minute cycle 
ergometer test as well as changes in endurance capacity in rugby players, were examined. In 
the triathletes using an active device (n=10), a significant reduction in resting heart rate, 
immediate post-exercise as well as recovery heart rate, one and three minutes after 
completing the cycle test was reported compared to those using a placebo device without a 
magnetic coil (n=4), while the rugby players using the Therahaler® O2 Gold  (n=8) showed a 
10.15% increase in performance in the sprint bleep test when compared to that of a control 
group (n=20).  
 
A large scale double-blind placebo-controlled clinical maximal cycle trial was thereafter 
conducted to determine if the Therahaler® O2 Gold improved peak power output and 
exercise time to exhaustion after four weeks of use.  Roberts (2007) reported that there was  
a significant 6.88% increase in the peak power output as well as a significant improvement   
(p< 0.05) in recovery heart rate and rate of perceived exertion (RPE) in the active group on a 
1500G magnetic device  (n=44) compared to that of the placebo group (n=59) and a group 







As the evidence of the efficacy of this magnetic breathing device in optimizing athletic 
performance, is however presently primarily based on unpublished and anecdotal reports 
with only one extensive double–blind placebo-controlled trial having been conducted 
(Roberts, 2007), a further double blind, placebo-controlled, cross-over study was designed to 
confirm these reports of performance benefits and begin an investigation into possible 
mechanisms which could explain the possible improvements in cardio-respiratory function in 
endurance athletes using this device. 
 
1.2  Primary Aim 
To determine the effects of 28 days of regular O2 Gold usage, according to the current 
specifications of the manufacturers, on the cardio-respiratory function of well-trained 
endurance athletes during a maximal exercise test. 
 
1.3  Secondary Objectives 
1. To determine the effects of regular use of the magnetic inhaler on the following 
parameters during and following an incremental treadmill exercise test to exhaustion: 
 
 peak power output and maximal running time on the treadmill 
 absolute and relative maximum oxygen consumption (VO2 max)   
 RPE, HR, VE , respiratory exchange ratio (RER) and O2 saturation at the workload at 
which VO2 max was reached 
a. submaximal minute ventilation (VE, L.min
-1
), absolute O2 uptake (VO2, 
L.min
-1
), heart rate (HR), rating of perceived exertion (RPE), and O2 
saturation  
 HR recovery during the first two minutes post exercise 
 
2.  To determine the effects of regular use of the magnetic inhaler on pre-exercise forced 
vital capacity (FVC), forced expiratory volume in one second (FEV1), FVC/FEV1 and forced 
inspiratory volume (FIV1). 
 
3.  To determine the effects of regular use of the magnetic inhaler on red blood cell indices, 
serum erythropoietin (EPO) and plasma interleukin-3 (IL-3) concentrations in pre-exercise 








1.4   Hypotheses 
In view of the apparent consensus in the literature, albeit by a limited number of published 
studies, regarding a performance enhancing effect following regular use of the magnetic 
inhaler, a positive alternative hypothesis was set for the objectives relating to this effect, 
namely,  
 
Twenty-eight days of regular use of the 1500G O2 Gold magnetic breathing device will 
improve 
 peak power output and maximal running time on the treadmill 
 pre-exercise test respiratory function, RBC and  Hb concentrations and Hct of 
endurance athletes  
 
In view of the lack of published research findings and consensus regarding the objectives 
concerning possible mechanisms for this, null hypotheses were set of the remainder of the 
study objectives, namely,  
 
Twenty-eight days of regular use of the 1500G O2 Gold magnetic breathing device will not 
affect  
 absolute and relative maximum oxygen consumption (VO2 max)   
 RPE, HR, VE , respiratory exchange ratio (RER) and O2 saturation at the workload 
at which VO2 max was reached 
 submaximal minute ventilation (VE,), absolute O2 uptake (VO2,), heart rate (HR), 
rating of perceived exertion (RPE), and O2 saturation 
 resting circulating IL-3 and EPO concentrations 






REVIEW OF THE RELATED LITERATURE 
 
2.1  Magnetism and Magnetic Therapy 
Magnetism is created primarily by the motion of electrically charged particles (Durney et al., 
1999). A magnetic field is a force field generated by these moving electrical charges (Saini 
et al., 1988). Figure 2.1 below represents how electrical charges behave in the absence and 
presence of a magnetic field. In permanent magnets, this is created by the quantum 
mechanical motion of electrons in the atoms, each of which produces a magnetic moment 
(Jackson, 1988). The strength of a magnetic field is its magnetic flux density, with the SI 
unit of measurement being the Tesla (T) (Nave, 2007). For a magnetic flux density of one 
Tesla, a force of one Newton must act on a one meter length of wire carrying one ampere of 
one current (Nave, 2007). One Newton of force is a very large force. Therefore a smaller 
unit of magnetic flux density is often used: Gauss (G) (1 Gauss = 1/10000 Tesla) (Nave, 
2007). The earth’s magnetic flux is 0.5 Gauss, whereas the strength of the magnetic field of a 







Figure 2.1  Moving electrical charges in the presence of a magnetic field.  
Adapted from: www.themagnetguide.com/magnetic-materials.html 
 
Many civilizations throughout history have used magnets and the magnetic field they create, 
to treat illness and enhance the lives of human beings (Roberts, 2008). Magnetic therapy has 
also been reported to be useful in treating ailments such as fractures (Sharrard, 1990), wound 
healing (Lee et al., 1993; Man et al., 1999), chronic pain (Valbona et al., 1997) and 
psychiatric disorders, including depression (Baker-Price and Persinger, 1996).  
 
For example, more recently the effect of static magnetic fields on cutaneous wound healing 
in an animal model was analysed by Henry et al. (2008). Standardized wounds were created 
on the backs of 33 Sprague-Dawley rats, which were divided into three groups to which a 23 
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gauss magnet, a sham magnet, or no magnet was positioned over the wound. Wounds in the 
magnet group healed in an average of 15.3 days, significantly faster than those in either the 
sham group (20.9 days, p=0.006) or control group (20.3 days, p<0.0001). Localized 
inflammation was induced via injection of inflammatory agents into rat hind paws (Morris 
and Skalak, 2008). Application of a 10 or 70 mT magnet for 15 or 30 minutes immediately 
following histamine induced oedema, resulted in a significant, 20–50% reduction in oedema 
formation.  Costantino et al. (2007) studied 40 patients with wrist fractures after applying a 
magnet of 12,500 G directly over the fracture in the plaster cast of the participants.  This 
resulted in bone callus formation that produced a 35% improvement in healing rates 
compared to standard time. The pain-relieving efficacy of static magnetic fields produced by 
200 G magnets compared with 50 G magnets were also examined in a double-blind, 
randomized, two-phase crossover study in patients with chronic lumbar radicular pain. Pain 
was rated on a scale of 1-10. A greater increase in pain was observed with use of the 200 G 
magnet (Khoromi et al., 2007).  Laszlo et al. (2009) examined antinociceptive activity in the 
writhing test in mice and concluded that a 3 T homogeneous static magnetic field of a 
clinical magnetic resonance system induces a significant pain-inhibitory effect and Butariu et 
al. (2009) confirmed improved neural function when they investigated the application of 
pulsed magnetic fields in the rehabilitation treatment of 20 participants with peripheral nerve 
lesions of the hand and reported an 11.1% improvement in peripheral nerve function. 
 
There is, however, limited information relating the use of magnetic therapy to enhance 
athletic performance (Roberts, 2004; 2007; Roberts et al., 2008). Bassett and Howley (1997) 
proposed that athletic performance may be enhanced by magnetic fields possibly by 
accelerating cell membrane substrate transport systems, elevating enzyme activity and ATP 
production.  It has been found to enhance nerve excitability (Hong, 1987), Hct and Hb 
concentration (Chater et al., 2006), collagen deposition (Zhang et al., 2000) and immune 
response (Jankovic et al., 1991). Further claims of an improved isometric exercise benefit for 
the inspiratory muscles (Roberts, 2004; 2007), a lower resting heart rate (HR;  Ryan, 2007), 
improved muscle repair (Zhang et al., 2000), bone mineral density (Costantino et al., 2007), 
post-exercise HR recovery (Ryan, 2007), vascular tone and tissue perfusion and general 





Little is however known of the exact mechanisms which are responsible for the reported 
elevation of RBC count, Hct and Hb concentrations, which may affect endurance capacity 
(Chater et al., 2006). Whether regular exposure to magnetic fields, for example, enhances 
RBC concentrations by affecting blood erythropoietin hormone concentrations or 
haematopoeitic growth factors, is unknown. 
 
Oxygen (O2) is the only gas that exhibits paramagnetic properties with molecular attraction 
and orientation in the presence of a magnetic field. This is caused by the electrons in motion 
in atoms forming microscopic current loops that are capable of forming magnetic fields of 
their own, a phenomenon that is recognised and utilised in Magnetic Resonance Imaging 
(Griffith et al., 1984).   Figure 2.2 is an enlarged diagrammatic representation of an oxygen 











Figure 2.2  Diagrammatic representation of an oxygen molecule.  




In the case of recently designed breathing devices containing magnets varying in strength 
from 1800 to 3000 Gauss, atmospheric O2 inhaled through the device, is thus ionized.  The 
charged O2 then passes through the lungs and onto the iron binding sites of Hb within the red 
blood cells. Miller (1977) found that magnetic fields reduce water surface tension, possibly 
by altering characteristics of hydrogen bonding equilibrium and may hold this charge for 24 
hours. The surface tension of water (Gerber, 2001) is affected as hydrogen bonding occurs 
when a negative O2 atom of one water molecule is attracted to the positive hydrogen atom of 
another water molecule. Water makes up the majority of blood therefore it is proposed that 
the charge may affect nutrient solubility and athletic performance (Miller, 1977). 
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Electron 
Inner electron shell, 2 electrons 













Figure 2.3  Diagrammatic representation of a haemoglobin molecule.  
Adapted from: http://gassama.myweb.uga.edu/ 
 
Hb is a molecule comprising an iron atom surrounded by a ring of hydrogen, O2 and carbon 
atoms which make up four polypeptide chains and the globin portion of the Hb molecule, as 
can be seen in Figure 2.3 above. Under conditions of neutral or alkaline pH, iron is found in 
the Ferric state (Fe
3+
) state and at acidic pH, the Ferrous state (Fe
2+
) state is favoured. The 
Fe
3+
 state is not readily soluble and the Fe
2+
 state favours O2 binding (Sakurai et al., 2000). It 
is suggested that O2 reduces haeme iron from its Fe
3+
 to its Fe
2+
 therefore gaining an electron 
and an O2 molecule. Thereby oxyhaemoglobin levels and active tissue O2 perfusion are 
increased (Sakurai et al., 2000).  
 
Zhernovoi et al. (2001) found that in some Hb molecules exposed to a magnetic field, the 
bond between nitrogen and iron atoms are disrupted, causing Hb activation. O2 may then be 
added to the free bond of the iron atom of activated Hb. The enhanced O2 carrying capacity 
of blood may be explained by the binding of two O2 molecules to the iron atom of Hb in the 
presence of a magnetic field, forming bioxyhaemoglobin. Bioxyhaemoglobin however, is 
dependent on a constant magnetic field, and decomposes when the magnetic field is 
removed. Formation of bioxyhaemoglobin also depends on the plasma concentration of 
dissolved O2 (Zhernovoi et al., 2001).  
 
2.2  Magnetic Breathing Device  
The O2 Gold magnetic breathing device, previously marketed as the Therahaler® O2 Gold, is 
a non-medicative magnetic breathing device that was initially developed by Bryan Speight, a 
member of the Royal Pharmaceutical Society of Great Britain in 1998, as an aid to treat 
asthma and in response to the results of research on the magnetic effects of O2 and O2 
transport. This early work was conducted by Prof Botiko of Moscow University and Dr B 
Shapiro, assistant professor, Department of Anaesthesiology from North-western Medical 
School (Shapiro, 1973).   






The generally accepted procedure for use of the device, which is schematically represented 
in Figure 2.4 below, is that patients/athletes are required to breathe in through the O2 Gold 
containing a solid magnet and fill their lungs to full capacity. Thereafter, are required to hold 
their breath for as long as reasonably possible, and then exhale. It is suggested that athletes 
should do this 25 to 30 times a day for the initial 4 weeks, whereas an asthmatic person is 
required to complete an 8 week period. Subsequently a maintenance program of twice a day 














Figure 2.4  Schematic representation of the O2 Gold magnetic breathing device.  
Adapted from: www.ammhealth.co.za/therahaler/effects.htm.  
 
2.3  Studies on the Effects of the O2 Gold on Athletic Performance  
The O2 Gold magnetic breathing device is firstly believed to help condition the inspiratory 
respiratory muscles. When air is inhaled through the device, it is designed to create slight 
resistance to such airflow. This increases the work of the respiratory muscles during the 
inhalation. Several different studies have indicated that exercise does induce respiratory 
muscle fatigue (Johnson et al., 1993; Mador et al., 1993) and that respiratory muscle fatigue 
can limit exercise performance (Mador et al., 1991). Respiratory muscle training, 
particularly inspiratory muscle training is therefore thought to enhance endurance exercise 
performance in both trained and untrained individuals (Boutellier et al., 1992; Splenger et 
al., 1998; Splenge, 1999). The potential inspiratory muscle training provided by regular use 
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the device itself and it is acknowledged by the author that such alternate factors do exist in 
contributing to improved endurance performance. 
 
The O2 Gold magnetic breathing device is firstly believed to help condition the respiratory 
muscles. When air is inhaled through the device, it is designed to create slight resistance to 
such airflow. This increases the work of one’s respiratory muscles during the inhalation. 
Several different studies have indicated that exercise does induce respiratory muscle fatigue 
(Johnson et al., 1993; Mador et al., 1993) and that respiratory muscle fatigue can limit 
exercise performance (Mador et al., 1991). Respiratory muscle training, particularly 
inspiratory muscle training is therefore thought to enhance endurance exercise performance 
in both trained and untrained individuals (Boutellier et al., 1992; Splenger et al., 1998; 
Splenge, 1999). The potential inspiratory muscle training provided by regular use of the O2 
Gold may therefore be more directly responsible for a benefit than the magnetism of the 
device itself and it is acknowledged by the author that such alternate factors do exist in 
contributing to improved endurance performance. 
 
Two initial pilot studies that were conducted using the magnetic breathing device were done 
on asthmatic patients by Drs Giereke and van der Linde, pulmonologists from Durban in 
1999 and 2001, respectively (Roberts, 2007).  In the first trial, Giereke found a significant 
reduction in the use of asthma medication as well as a reduction in the number and severity 
of asthma attacks (Geireke, 1999).  In the second study by van der Linde, 45 asthmatics were 
assessed according to quality of life. The use of the Therahaler® O2 Gold resulted in a 
reported improvement in the quality of life and a 71% reduction in the use of reliever 
medication, with no side effects reported (van der Linde, 2001).  There are also anecdotal 
reports of a number of the active trial patients that indicate an improvement in their physical 
performance and a few athletes reported running their personal best times while using the 
Therahaler® O2 Gold (Roberts 2004). 
 
In terms of the effect of regular prolonged usage of the Therahaler® O2 Gold on athletic 
performance, the first pilot trial was conducted by Angus Ryan, a Biokinetisist, on 14 
triathletes in 2003. As described by Roberts (2004; 2007), a heart rate recovery test was 
conducted on 10 athletes who were given an active Therahaler® O2 Gold device and four 
who were given placebo devices (identical breathing devices without a magnetic coil). A 15 
minute cycle ergometer test was completed and heart rate responses were analysed, both 
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before and after the standardized cycle ergometer test at the commencement of the study and 
again after 4 weeks. As is shown in Table 2.1, the O2 Gold group showed a significant 
reduction in resting heart rate immediately after completing the 15 minute cycle, as well as 
recovery heart rate one and three minutes after completing the test, when compared to the 
placebo group (Ryan, 2007). Table 2.1 details the findings of his study. 
 
Table 2.1  Heart rate response to regular use of the Therahaler®  O2 Gold.  
Adapted from: Ryan (2007).  
 
Test Parameter Athletes using O2 Gold  
(n=10) 
Athletes using Placebo  
(n=4) 
 At Start After 4 weeks % Change At Start After 4 Weeks % Change 
Ave resting heart 
rate (bpm) 
66.14 61.80 -7.35 64.75 66.50 +1.02 
Ave resting heart 
rate after 15 min 
exercise (bpm) 
160.20 150.50 -6.00 163.75 165.00 -0.91 
Ave resting heart 
rate after 1 
minute rest (bpm) 
122.70 105.60 -13.90 123.00 124.25 +1.00 
Ave resting heart 
rate after 3 
minute rest (bpm) 
91.30 81.10 -11.70 92.25 98.25 +6.25 
 
In the same year (2003), Roberts also conducted controlled testing on a 28-man rugby squad 
over a four week exercise regime during which the sprint bleep-test was used to measure 
endurance levels.  At the end of the four weeks the Therahaler® O2 Gold users (n=8) showed 
a 24.44% increase in performance in the bleep test whilst the control group (n=20) showed a 
14.29% increase (Roberts, 2004; 2007).  
In a further unpublished local pilot study described in Roberts (2004), blood gas, Hb and 
oxyhaemoglobin levels were assessed in seven participants using the Therahaler® O2 Gold 
for four weeks. Following extraction of baseline arterial blood samples, participants were 
required to use the Therahaler® O2 Gold according to the manufacturer’s recommendations 
at 30 minute intervals during waking hours and again report for arterial blood sampling after 
two and four weeks. Although the average oxyhaemoglobin levels rose over the four weeks 
from 93.69 to 94.75%, this increase only reached borderline statistical significance (p = 
0.0516) and it is not certain whether the mean increase confirms a clinically significant 
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therapeutic effect of improved bonding of the oxygen to the Hb. Interestingly, the PCO2 
levels were  not significantly disturbed (p=.3184), ruling out the possibility of a possible  
improvement in mean oxyhaemoglobin concentrations being the result of hyperventilation.   
In a subsequent double-blind baseline maximal cycle trial undertaken to determine if the 
Therahaler® O2 Gold improved peak power output and exercise time to exhaustion after four 
weeks of use,  131 healthy participants were recruited from running, cycling, swimming, 
triathlon, hockey and rugby clubs (Roberts, 2007; Roberts et al., 2007). Following baseline 
maximal cycling tests, the participants were divided into three groups, a placebo group 
(n=52) and two active groups, on a 1500G (n=44) and on a 3000G Therahaler® O2 Gold 
(n=35). The participants were requested to use the device every 30 minutes throughout the 
day while awake, and to record their daily use as well as training volume and intensity. They 
were then retested two and four weeks after device use. Roberts (2007) found that after two 
weeks there was no significant difference in the peak power output and in exercise time to 
exhaustion in the three groups (p>0.05). However, after four weeks of use there was a 
significant 13.78% increase in the peak power output in the 1500G group (p=0.0004) 
compared with a 6.90% increase in the placebo group (p=0.0122), but no significant change 
in the 3000G group (p=0.1). After four weeks there was also a significant improvement in 
the mean exercise time to exhaustion in all three groups; the mean improvement in the 
1500G group was 85 seconds (p<0.0001), in the 3000G group, 53 seconds (p=0.027) and in 
the placebo group, 53 seconds (p<0.001).  
 
Although there was also no significant difference in the HR response to exercise in the 
placebo and 3000G group (p>0.1), in the 1500G group after four weeks of usage, there was 
a significant reduction in the heart rate after four and a half minutes and after seven minutes 
of exercise (p<0.05). After two weeks there was a significant reduction in the rating of 
perceived exertion (RPE) after four and a half minutes of exercise in the 1500G group 
(p<0.05), and after four weeks there was a significant reduction in the RPE after four and a 
half minutes in the 1500G and 3000G group (p<0.05; Roberts, 2007).  
 The author acknowledges that the above reviewed literature relies primarily on  
unpublished, anecdotal and often small-scale works, with only one extensive double blind 
placebo-controlled trial (also unpublished), having been conducted to date.  It can therefore 
be concluded that further work in which major extraneous confounders such as changes in 















findings of the above-mentioned studies. Furthermore, to the author’s knowledge, no work 
examining possible mechanisms which may contribute to the reported apparent benefits of 
magnetic therapy on athletic performance, has yet been published.    
2.4  VO2max 
The term “maximal oxygen consumption” (VO2max) was first coined and defined by Hill 
and Herbst in the 1920s (Warpeha, 2003). In 1923 Hill and Lupton postulated that (i) there is 
an upper limit to O2 uptake, (ii) there are inter-individual differences in VO2max and (iii) a. 
high VO2max is a prerequisite for success in middle and long distance running with VO2max 
being limited by the ability of cardiorespiratory system to transport O2 to the muscles 
  
Traditionalists supporting these early theories of a physiological upper limit to the body’s 
ability to consume O2, claim that VO2max, the highest rate at which one can transport and 
utilise oxygen, is the most widely accepted determinant of ability in endurance sports 
(Bassett and Howley, 1999). VO2max thus remains one of the most commonly measured 
parameters in the basic and applied physiological sciences.  
 
Absolute values of VO2max are typically 40-60% higher in men than in women (Hyde et al., 










 (Heywood, 1998; Guyton and Hall, 2011). These scores 
can improve with training and decrease with age, although the degree of trainability also 
varies very widely. Conditioning has been reported to double VO2max in previously 
untrained individuals, and to only marginally improve it in others (Kolata, 2992; Claude et 
al., 2007). In sports in which endurance is an important component in performance, such as 
cycling, rowing, cross-country skiing, swimming and running, world class athletes typically 













 (Noakes, 2001). 
 
According to the classical, traditional premise, the capacity of the heart, lungs and blood to 
transport oxygen to the working muscles, as well as the muscles’ ability to utilize that 
oxygen during exercise determine VO2max (Bassett and Howley, 1990). VO2max is 
therefore, also defined as the product of Qmax and (CaO2 – CvO2) where Qmax is the maximum 
cardiac output, CaO2 is the arterial oxygen content, and CvO2 is the venous oxygen content.  






physiological factors would therefore include the inspiratory capacity of the lungs, 
pulmonary diffusing capacity of O2 into the pulmonary circulation, O2 transport to the active 
muscles which is dependent on maximal cardiac output and the O2 carrying capacity of the 
blood and skeletal muscle characteristics including diffusion capacity, mitochondrial 
enzymes, and capillary density (Bassett and Howley, 1990). These limiting physiological 
















Figure 2.5  Physiological factors that potentially limit maximal oxygen uptake in exercising 
humans. Adapted from: Bassett and Howley (1999).  
 
 
The first four of these factors are commonly classified as the “central” factors, while those 
relating to uptake of oxygen by skeletal muscle are termed the “peripheral” factors. Although 
both sets of factors suggest that availability of O2 limits muscle fiber oxidative ATP 
production, traditionally, exercise physiologists that support the traditional/ classical theory 
of the determinants of VO2max are divided into proponents of the “central” and “peripheral” 
perspectives.  
 
2.4.1  Central Factors 
The pulmonary system consists of the lungs, responsible for saturating the arterial blood 
with O2. It is well accepted that healthy lungs are able to saturate the arterial blood with O2 
extremely well (Guyton and Hall, 2011). Hill et al., however, predicted that a significant 
drop in arterial saturation does not occur based on the appearance of their participants in the 
early 1920’s and modern researchers have verified that the pulmonary system may indeed 
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limit VO2max under certain circumstances (Bassett and Howley, 1999).  Dempsey et al. 
(1984) showed that elite athletes are more likely to undergo arterial O2 desaturation during 
maximal work compared with normal individuals. The reason for this has been related to the 
fact that trained individuals have a higher cardiac output than untrained individuals, and this 
therefore leads to a decreased transit time of the red blood cells in the pulmonary capillary. 
Consequently there may not be enough time to saturate the blood with O2 before it exits the 
pulmonary capillary. However this pulmonary limitation in highly trained athletes can be 
overcome with O2-enriched air (Dempsey et al., 1984), a fact which may be of great 
significance in terms of the potential effect of usage of a magnetically charged breathing 
device.  
 
In 1923 Hill et al. proposed that cardiac output, the product of the stroke volume and heart 
rate, was the primary factor explaining individual differences in VO2max. Today it is known 
that the normal range of VO2max values observed in sedentary and trained men and women 
of the same age is due primarily to variations in maximal stroke volume, given that 
considerably less variation exists in the maximal heart rate which also decreases with age, 
although to a much lesser extent (Hill et al., 1923; Bassett and Howley, 1999).  
  
It has been estimated that 70-85% of the limitations in VO2max are linked to the maximum 
cardiac output (Cerretelli and Prampero, 1987). Longitudinal studies have shown that the 
training induced increases in VO2max result primarily from an increase in maximal cardiac 
output, rather than a widening of the systemic (a-v) O2 difference, which is regarded as a 
peripheral factor and will be discussed below (Bassett and Howley, 1999). 
 
Another “central” factor involved in oxygen delivery is the muscle blood flow. During 
exercise there is a redistribution of cardiac output so that muscle blood flow can increase 
from a resting volume of ±1L.min
-1
 (20% of cardiac output) to around 20L.min
-1
 (80% of 
cardiac output) during maximal exercise. However vasodilation of the periphery cannot be 
unlimited as this would cause a drop in blood pressure. Increasing the demand for peripheral 
blood flow to an additional vascular bed by adding arm exercise to high intensity leg 
exercise will cause a reduction in leg blood flow, despite an unchanged work rate. This 
therefore indicates that the capacity of the periphery to vasodilate is actually greater than that 
elicited near exhaustion under normal physiological conditions. Muscle blood flow can also 







Since endurance training increases both muscle capillarity and VO2max, it is possible that 
inadequate muscle capillarity could limit the VO2max of untrained individuals, although an 
increase in muscle bulk alone would show an increase in VO2max independent of any 
increases in muscle capillarity.  
 
The next step in the physiological chain would then be the extraction of oxygen from the 
blood by the working muscles. The finding that femoral venous oxygen content is not close 
to zero at maximal exercise implies that oxygen delivery is adequate, but the muscle capacity 
for oxygen extraction may be exceeded. The mechanism of oxygen extraction includes its 
dissociation from Hb, diffusion from the red blood cells into the muscle cells and finally 
diffusion and transport within the muscle cells to the mitochondria.  
 
It would therefore be interesting to establish whether an improvement in central factors 
which govern the maximum O2 carrying capacity of the blood, including increased 
respiratory function (resulting in improved pulmonary ventilation), erythrocyte production, 
Hct, Hb and oxyhemoglobin concentration are related to increases in maximum O2 uptake 
during intense bouts of endurance exercise involving the large muscle groups. 
 
2.4.2  Peripheral Factors 
While O2 transport to the active muscles is dependent on central factors including the 
pulmonary diffusing capacity, maximal cardiac output and O2 saturation or O2 carrying 
capacity of the blood, peripheral factors including O2 diffusion into the muscle and 
mitochondrial oxidative capacity have also been considered as possible limitations of 
VO2max, particularly during exercise with small muscle groups (Ferretti et al., 1997). 
 
Systemic O2 extraction is a possible peripheral factor that can affect the amount of O2 
transported to the active muscles (Bassett and Howley, 1999). During maximum exercise 
almost all of the available O2 is extracted from the blood perusing the active muscles. The O2 
content of arterial blood is approximately 200mL O2.L
-1
 whereas in venous blood draining 
maximally working muscles it falls to about 20-30 mL O2. L
-1
. This therefore indicates that 
there is little O2 left to be extracted out of the blood during heavy exercise.  
 
Honig et al. (1992) however presented evidence for a peripheral O2 diffusion limitation in 
















site of resistance to O2 diffusion occurs between the surface of the red blood cells and the 
sarcolemma. They reported a large drop in PO2 over this short distance. They therefore 
concluded that O2 delivery is not the limiting factor. Without a peripheral diffusion gradient, 
O2 uptake will not increase. Within the muscle fibers the mitochondria are the site where O2 
is consumed in the final step of the electron transport chain. In theory, doubling the number 
of mitochondria should double the number of sites for O2 uptake in the muscle (Bassett and 
Howley, 1999). However human studies show that there is only a modest increase in 
VO2max (20-40%) despite a 2.2-fold increase in mitochondrial enzymes (Saltin et al., 1977).  
 
Proponents of the classical traditional theory therefore maintain that “VO2max sets the upper 
limit for performance in endurance events” rather than being “the best predictor of athletic 
ability” (Basset and Howley, 1997). VO2max is directly linked to the rate of ATP generation 
that can be maintained during a distance race, although distance races are not run at 100% 




) that can be 
maintained during the run, which is determined by the participants VO2max and the percent 
of VO2max at which the subject can perform. For example, to complete a 2:15 marathon, a 
VO2 of about 60mL.kg.min
-1
 must be maintained throughout the run. Therefore even if a 





for the above performance. However, since the marathon is typically run at about 80–





. Hence VO2max is thought to set the upper limit for energy production in endurance 
events, but does not determine the final performance. 
 
2.4.3  An Alternative Perspective 
Recently a school of thought has emerged which proposes that local muscle factors 
independent of O2 delivery may limit the VO2max test by halting maximal exercise before 
the O2 delivery systems are taken to their maximal capacity (Hawley et al., 1995). This 
muscular limitation could be due to the ability of the mitochondria to utilize O2. Hawley et 
al.(1995), also thought that the proposed muscular limitation may be independent of O2 -
supply and utilization and dependent rather on the proper function of the muscle fiber 
excitation and acto-myosin interaction and relaxation.   
 
Factors determining the maximal work rate achieved during the maximal exercise test are 







fatigued state. Under conditions in which the products of high rates of ATP utilizations begin 
to accumulation, the rate of cross-bridge cycling is reduced by a decrease in myosin-ATPase 
activity. The subsequent decrease in the rate of ATP hydrolysis spares intracellular ATP 
concentrations. Accordingly, muscle ATP concentrations will always be maintained above 
the critical value at which irreversible energy depletion could develop. It may be that 
maximum high intensity exercise in humans is terminated by a regulated process that 
specifically presents the development of ATP depletion in the active muscles. However 
muscle ATP concentrations are preserved in normal individuals even during maximal 
exercise under ischemic condition. Therefore even in participants with mitochondrial 
myopathies who lack the oxidative capacity to produce ATP at very high rates, exercise 
terminates well before the onset of ATP depletion (Bassett and Howley, 1999).  
 
Muscle work rate or power output is not only a function of the myosin ATPase activity and 
myofibrillar cross-bridge turnover rate, but also the number of interacting cross-bridges and 
the force produced by each. The metabolites which accumulate during high rates if ATP 
utilization, such as hydrogen ions and phosphate, also decrease the force produced per cross-
bridge and thus a potential decreased maximal power output of the muscles. These 
metabolites may also decrease the rate of sarcoplasmic reticulum ATPase activity with the 
result that production of calcium from the intracellular space is less efficient and relaxation 
is impaired. Hawley et al. (1995) therefore concluded that exercise tests that are designed to 
elicit a VO2max may potentially be inhibited by these intramuscular factors before the 
classical “central” and “peripheral” factors of O2 utilization have reached an upper limit. 
 
2.4.4  VO2 max Versus “Running Economy” 
Mechanical efficiency is the ratio of work done to energy expended. The term “running 
economy” is used to express the oxygen uptake needed to run at a given velocity. This can 




) versus running velocity (m.min
-1
) or by 





; Bassett and Howley, 1999). As was pointed out in the rebuttal to 
this (Noakes, 1998), when one examines the fastest four runners (10 km in 30.5–31 min) 




 at 268 
m.min
-1
), suggesting a lack of association between the variables. A comprehensive 
explanation of how VO2max and running economy interact to affect running velocity was 









2.6 presents a plot of male and female runners equal in terms of VO2max, but differing in 
running economy (Daniels and Daniels, 1992). A line was drawn through the series of points 
used to construct an economy-of-running line, and was extrapolated to the subject’s 
VO2max. A perpendicular line was then drawn from the VO2max value to the x-axis to 
estimate the velocity that subject would have achieved at VO2max. This is an estimate of the 
maximal speed that can be maintained by oxidative phosphorylation. In this example, the 
difference in running economy resulted in a clear difference in the speed that could be 












Figure 2.6  Comparison of male and female runners of equal VO2max where males are 
significantly favoured in economy and VO2max. Adapted from: Daniels and Daniels (1991).  
 
2.5  Blood Cell Status and its Regulation 
 
 2.5.1  The Role of Erythropoietin 
Oxygen carrying capacity is an important component of the ‘central’ factors which 
determine VO2max. This is dependent on the RBC and Hb concentrations. A factor to be 
examined would therefore include the possibility that previously shown increased 
erythrocyte and Hct levels are related to increases renal production of the hormone, 
erythropoietin (EPO). Erythropoietin, also known as erythropoetin or erthropoyetin or EPO, 
is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. This 
would assist in clarifying the currently opposing theories that exist regarding the actions of 
magnetic fields, which have on the one hand, suggested increased O2 availability (Saini et 







The adult human kidney is the main organ for production and release of EPO, which 
stimulates the proliferation, differentiation and maturation of the erythroid precursors in 
bone marrow (Jelkmann, 2003), therefore increasing the production of red blood cells. About 
120 million erythrocytes are destroyed every minute in the adult human body. This occurs 
mainly in the spleen, liver and bone marrow (Ratcliffe et al., 1996).  
 
To avoid anaemia, equilibrium between the destruction and production of new red blood 
cells has to be maintained. Under conditions of constant O2 availability the glycoprotein 
EPO is the main humoral factor responsible for maintaining a normal blood erythrocyte 
count (Gunga et al., 2007). 
 
EPO concentrations are expressed as milliunits per milliliter (mU.mL
-1
). The normal range 
of EPO levels in human serum or plasma is in the order of 5-25 mU.mL
-1
, but EPO levels 
can be increased 100- to 1000-fold in response to hypoxia or blood loss. In healthy 
individuals and patients with various types of anemia (e.g. caused by blood loss, hemolysis, 
iron deficiency, aplastic bone marrow or by nutritional deficiencies), EPO levels are 
inversely correlated with hematocrit and hemoglobin levels, and reflect the reciprocal 
relation between oxygen supply and EPO production rate (Wognum, 2011). 
 
As endogenous renal EPO production occurs mainly in response to hypoxia, it is under 
hypoxic conditions, such as training at altitude or with O2 depleted gas and living in O2 
depleted tents,  that athletes have been able to increase their production of EPO and thus in 
return increase their red blood cell count. This therefore results in an increase in Hb 
concentrations, which will ultimately result in the fundamental increase in O2 carrying 
capacity and availability of O2 to the active skeletal muscle. It would therefore be interesting 
to ascertain whether the mechanism by which the reported increases in Hct levels are related 
to magnetically induced increases in endogenous production of EPO despite the apparently 
contradictory findings that magnetic therapy has been shown to increase O2 availability.  
 
2.5.2  Interleukin-3  
Another potential mediator of the regulation of red blood cell production is via systemic 
concentrations of interleukin-3 (IL-3). This is a cytokine protein signaling molecule 
produced by T cells and mast cells, which acts as a broad spectrum haematopoeitic growth 










and granulocytes (Guyton, 2011). It is therefore of interest to ascertain whether regular 
exposure to a magnetic field over a 28 day period, will increase systemic concentrations of 
this cytokine, and thereby account for the previously described increase in RBC count 
reported by Chater et al. (2006). 
 
2.6  Criteria used to determine the endpoint of a maximal exercise test 
A phenomenon sometimes encountered in elite endurance athletes is the VO2max plateau as 
opposed to a peak VO2 which is commonly encountered in less well trained athletes. When 
an athlete is challenged to progressively increasing workloads, with sufficient time for 
recovery between each increment of work, a linear relation between workload and oxygen 
intake occurs. Ultimately, maximal oxygen intake per unit of time is reached. Beyond this 
point the workload can usually be increased even further, but oxygen intake levels off or 
declines. This is commonly referred to as the VO2max plateau (Mitchell et al., 1957).  
 
Considerable variation in the achievement of a plateau in VO2 has been reported in literature. 
For example the percentage of participants who achieve a plateau has been reported at 90-
100% (Taylor et al., 1955), 60-80% (Sidney et al., 1977) and ≤50% (Froelicher et al., 1974). 
Therefore a variety of factors must be considered when making a judgement about each 
individual case or difficulties encountered in achieving a plateau in oxygen uptake. These 
include the population being studied, as children, unfit and elderly people are more likely to 
only reach VO2 peak when the test needs to be stopped due to exhaustion before they have 
reached their true VO2max. Trained and untrained people also display varied oxygen uptake, 












Figure 2.7  The comparison in VO2 peak reached in trained and untrained individuals. 











Pulmonary respiratory gas-exchange ratios (RER) defined as CO2 
production/O2 consumption is used as a secondary criterion for having reached VO2max. It is 
based on the reaction between a rise in plasma hydrogen ion (H
+
) concentration and plasma 
bicarbonate (HCO3
-
). As the CO2 is generated ventilation increases thus increasing the RER 
(ACSM, 9
th
 edition). The use of an RER value ≥1.15 as a criterion for achieving VO2max 
can be traced back to a study by Issekutz et al. (1961).  
 
Niekamp et al. (2012) conducted a study to assess whether diet affects RER changes during 
exercise. 57 sedentary individuals between 47 and 63 were used. The study concluded that a 
diet which promotes systemic alkalinity would cause an RER of 1.10 to be more easily 
achieved therefore resulting in a peak maximal oxygen uptake elicited in an incremental 
exercise test. RER is heavily influenced by CO2 production from acid buffering by the 
bicarbonate buffer system during maximal exercise. Therefore an RER of greater than 1.15 
in the most commonly accented value for termination of a test whereby a “true” VO2max 
will be reached. 
 
The achievement of a percentage of the age adjusted maximal heart rate is the most 
problematic criterion for the termination of a maximal exercise test. The standard deviation 
associated with the estimate is approximately ±11b.min
-1
 therefore making it a very difficult 
standard to justify (Londeree and Moeschberger, 1984). Participants in the lower half of this 
distribution would therefore not be able to achieve their heart rate standard, even when 
working maximally. While those at the other end of the distribution would achieve the 
estimate while working at submaximal work rates. It is for this reason that the American 
College of Sports Medicine states that predicted maximal heart rate should not be used for an 
absolute end point in the termination of a maximal exercise test (Howley et al., 1995). 
  
RPE is another frequently used criterion to end the test. As a measure of general fatigue that 
the person feels, it is measured on a scale of 1-10 or 4-20 (Borg, 1982). Perceived exertion 
can be defined as “the act of detecting and interpreting sensations arising from the body 
during physical exertion”. A persons’ perception of physical exertion allows them to monitor 
feelings of exercise intensity by sensory feedback; such internal feedback allows an 
individual to pace themselves appropriately during a specific bout of exercise or physical 





In conclusion a combination of the presence of at least three of the abovementioned criteria, 
is therefore generally used to determine the point at which the test should be terminated 
(Bassett and Howley, 1999).  
 
2.7  Blood Pressure 
It is well accepted that arterial blood pressure (BP), the pressure exerted against walls of the 
arteries, is dependent on cardiac output and total peripheral resistance (Guyton, 2011). One 
of the most frequently reported health benefits of regular participation in endurance exercise 
is lower resting BP, with the greatest effects seen in those with borderline hypertension 
(Fagard, 1993; 1999). Fagard (1993) noted that ‘aerobic’ exercise training decreased BP 
along a continuum with systolic (SBP) and diastolic (DBP) BP lowered by an average of 
3mmHg in individuals with normal BP, 6 and 7mmHg in those with high normal BP, 
respectively.  
 
Dynamic aerobic training including cycling, walking, jogging and running at a relatively low 
intensity e.g. 50% VO2 max, for an average of 30 minutes per day on five days in a week, 
can promote the lowering of clinical blood pressure during the post-exercise period in both 
hypertensive and normotensive participants. This phenomenon has been called post-exercise 
hypotension (PEH) and is characterized by a sustained decrease in blood pressure after a 
single episode of exercise (Pescatello et al., 2004).  
  
Several mechanisms have been proposed for the hypotensive efficacy of regular exercise. 
Studies by Japanese investigators suggest that the blood pressure reduction is initiated by 
volume depletion, induced by activation of the renal kinin system, dopamine, and 
prostaglandin systems. A subsequent reduction in sympathetic activity might be involved in 
the maintenance of the blood pressure reduction (Miura, 1994).  Jennings (1997) on the other 
hand, suggests that in Caucasians the primary events are an improvement of endothelium-
mediated vasodilatation (via release of dilatory agents including nitric oxide) and an increase 
in systemic arterial compliance in large vessels, although increases in arterial compliance are 
not always found. This changes the afferent input to the arterial baroreceptors. The result 
could be a reduced sympathetic outflow to the renal bed which could counterbalance any 
tendency to an increase in blood volume and thus blood pressure. It is quite possible that the 
antihypertensive mechanism of exercise training differs among populations depending on the 




that an attenuation of the cardiopulmonary baroreflex control of skeletal muscle vascular 
resistance after training at 70% VO2max compared with training at 50% VO2max may 
contribute to the less pronounced hypotensive efficacy of higher intensity exercise compared 
with lower intensity exercise. 
 
Microcirculation is the flow of blood through the microvasculature, including the arterioles, 
capillaries, and venules. It is these vessels that nourish the body’s tissues and organs. Two 
important functions of this circulatory system are to alter blood flow according to the 
varying metabolic requirements of the tissues it serves and to stabilize blood flow and 
pressure by making local regulatory adjustments (Zweifach, 1977). Several attempts have 
been made to explore the parameters of microcirculation and microvasculature when tissue 
and/or blood vessels have been exposed to a magnetic field (MF) (McKay et al., 2007). As 
previously mentioned many of the health benefits of magnets have been associated with the 
polarity of the static magnetic field (SMF). The negative and positive poles of magnets are 
believed to produce opposite physiological effects.  
 
The biological effects of MFs have often been linked to nitric oxide (NO). It is believed that 
NO may also be the molecule responsible for the changes in vessel diameter following MF 
exposure (McKay et al., 2007). In an experiment by Okano and Ohkubo (2001), blood 
pressure changes associated with SMF exposure were investigated in conscious rabbits. 
When blood pressure was increased using a nitric oxide synthase (NOS) inhibitor which 
resulted in vasoconstriction, exposure to a SMF caused a significant decrease in blood 
pressure during and post-exposure. This led to a significant increase in blood flow, measured 
using microphotoelectric plethysmography, after 10 minutes of exposure through to 40 
minutes post-exposure (Okano and Ohkubo, 2001), and was attributed to the vasodilatory 
effect of SMF exposure, it was therefore suggested that this may be related to the endothelial 
release of NO. 
 
This magnetic effect was again tested by Okano and Ohkubo (2003) on genetically 
hypertensive rats. At seven weeks of age, the rats were continuously exposed to a SMF (10 
or 25 mT) for 12 weeks. Throughout the 3rd to 5th weeks of SMF exposure, significant 
antipressor effects on mean blood pressure were found using the tail-cuff method. No 
differences in mean blood pressure were found between the two MF intensities that were 
tested. Hormone analysis revealed that the 10mT SMF (at five weeks of exposure) reduced 
25 
 
angiotensin II by 65.3% and aldosterone by 39.6%. The 25mT SMF (at five weeks of 
exposure) reduced angiotensin II by 63.8% and aldosterone by 36.6%. These reductions 
disappeared at 12 weeks of exposure. 
 
Okano and Ohkubo (2005) did further research into the effect of a stronger SMF (180 mT) 
implanted in the neck of spontaneously hypertensive rats. Hypertensive rats that were 
exposed to the SMF (14 weeks) had a mean blood pressure reduction (tail-cuff 




 weeks of exposure. The 
SMF also inhibited the decrease in baroreflex sensitivity that was observed in sham animals 
during the 5th–8th weeks of exposure. When nicardipine (Ca
2+
 channel blocker) was 
administered to decrease blood pressure, the application of the SMF further enhanced this 
decrease in mean blood pressure by 6.9% during weeks 1–8 of exposure. These results 
suggested that the SMF synergistically antagonized Ca
2+
 influx through Ca
2+
 channels.  
 
The investigation by Okano and Ohkubo (2005) indicates that the homeostatic effect of MFs 
might influence NO pathways. When genetically hypertensive rats were exposed to a SMF 
(1 or 5 mT) for 12 weeks, blood pressure, the concentration of NO metabolites, angiotensin 
II, and aldosterone were reduced. Specifically, exposure to the SMF reduced blood pressure 
during weeks 3–6. Hypertensive rats are known to have increased levels of NO metabolites, 
most likely due to the upregulation of NOS. Exposure to the 5 mT SMF for 6 weeks 
significantly reduced the concentration of NO metabolites by 73.2%. The 1 mT SMF did not 
have an effect on the NO metabolites. At three weeks, the 5mTSMF reduced angiotensin II 
by 51.1% and aldosterone by 40.2%, and at six weeks reduced angiotensin II by 58.2% and 
aldosterone by 72.2%. Similar significant reductions in angiotensin II and aldosterone were 
seen with the 1mT field. At 12 weeks, all effects on the NO metabolites, angiotensin II, and 
aldosterone disappeared. 
 
2.8  Heart Rate 
As previously mentioned, a study conducted by the Ryan (2007) on the effect of using the 
Thrahaler® O2 Gold to improve the heart rate response during exercise in 14 triathletes was 
performed. In this study, the group using the magnetic breathing device showed a significant 
reduction in resting heart rate, heart rate immediately after completing the 15 minute cycle, 





According to Colbert et al. (2009), fifty six studies have been conducted on the effects of 
static magnetic field therapy, in both patient populations and in healthy volunteers. In the 56 
studies, 39 different physiological or pathological conditions were represented. The 
physiological outcomes measured included improvement in muscle strength, muscle 
soreness post exercise, postural sway, fine touch, blood flow and heart rate and blood 
pressure.  
 
A study by Hinman (2002) compared HR and BP responses among healthy participants as 
they rested on pads containing magnets of negative polarity, magnets of positive polarity or 
placebo magnets. These physiological measures were selected because Philpott (1998) 
claimed that the heart is the most responsive tissue to the stress or anti-stress fields created 
by magnets. He stated that a significant (10 point) decrease in HR will occur within a few 
minutes of exposure to a negative SMF. Another further study by Jehenson et al. (1998) 
confirmed this as they reported a significant increase in cardiac cycle length (i.e. decrease in 
HR) following exposure to a high-intensity SMF (20 000 gauss) in a magnetic resonance 
chamber. However, other participants who were exposed to a weaker SMF (10 000 gauss) 
experienced no changes in HR or rhythm. 
 
Hinman (2002) therefore concluded that the changes in HR and BP that occurred in the 
participants within the study did not differ in relation to the type of pad on which they lay, 
and none of these changes were more than one might expect to find in a normal individual at 
rest. All participants experienced a slight reduction in both HR and BP that was most likely 
due to a general relaxation response. Thus, these findings do not support Philpott’s assertion 
that exposure to a negative SMF will gradually slow the HR by 10 bpm. Overall Hinman’s 
findings suggest that healthy people who lie on either positive or negative magnetic pads, 
experience no significant deviations in their HR or BP. 
 
2.9  Pulse Oximetry 
A pulse oximeter is a device intended for the non-invasive measurement of arterial blood 
oxygen saturation (SaO2) and pulse rate. Pulse oximeters use a light source and photodiode 
light detector to measure the amount of light passing through an arteriolar bed. SaO2 can be 
estimated noninvasively because the light-absorbing characteristics of haemoglobin differ 




Pulse oximeters are commonly used during exercise in clinical and research settings to 
provide a noninvasive, continuous estimate of the oxyhemoglobin saturation of arterial 
blood. Arterial oxyhemoglobin saturation indicates the degree of arterial blood oxygenation 
(Mengelkoch et al., 1994). However, although well accepted for use in resting participants, 
using pulse oximetry during exercise for accurate measurement of SaO2 has been 
problematic for several reasons. First, depending on the sensor site, sensors are subjected to 
varying degrees of motion resulting in signal corruption and thus inaccurate estimations of 
saturation (Plummer, 1995). Furthermore, sensors placed on the digits are even more 
susceptible to this problem especially during cycle because gripping the handlebars results in 
weakening or even complete loss of signals (Plummer, 1995).  
 
2.10  Conclusion 
This review of the literature indicates that there is evidence in favour of possible therapeutic 
benefits when the human body is exposed to static magnetic fields. As much of the evidence 
however remains inconclusive and in some cases contradictory, confirmation in further well 
controlled studies on athletes is required. The exact mechanisms by which a magnetic 
breathing device may affect endurance performance and associated physiological responses 
including improved endurance capacity, enhanced RBC and Hb cell concentrations, O2 – 
carrying capacity, VO2max and lowered heart rate and blood pressure responses to exercise 








3.1  Ethical Clearance and Study Design 
The study was designed as a double blind, placebo-controlled, cross-over laboratory trial 
preceded by a baseline assessment.  
 
Full ethical clearance for this study was obtained from the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (Ethics Clearance No: BFC 82/012) 
(Appendix A).  
 
In order to implement the double-blind nature of the study, devices were coded by the 
manufacturer so that the researchers as well as participants were not aware which devices 
were the placebos and which were the active. Only after completion if the trial were the 
devices decoded. 
 
3.2  Participants 
All volunteers from three sporting clubs who met inclusion criteria (n= 18) were included in 
the original sample. Clubs were contacted and informed about the study via information 
meetings as well as visual representation. Participants then volunteered to participate in the 
study, and were only included if inclusion and exclusion criteria were met. 
 
The inclusion and exclusion criteria for the participants were as follows:  
INCLUSION CRITERIA EXCLUSION CRITERIA 
 Healthy males  
 Aged >18 and <45 years old 
 Willing participants who consent 
to participate in the entirety of the 
trial, which included regular 
prescriptive O2 Gold use,  three 
maximal exercise tests on a 
treadmill,  and provision of small  
venous blood samples at baseline 
and after the active and placebo 
Women 
Age <18 and >45 years old 
Any contraindications to exercise as per 
Physical Activity Readiness Questionnaire 
(PAR-Q) 
Regular or chronic use of medication 




Recreational or professional endurance 
runners who were prepared to maintain 
their weekly training distance during the 







Implanted metal or medical devices 
Use of performance enhancing agents  
Consumption of any drug, caffeine or 
alcohol on test days 
Any bleeding disorders 
Vegetarians  
Regular consumption of any form of 
nutritional supplementation (e.g. 
multivitamins, calcium, magnesium) 
 
After completing baseline assessments eighteen athletes were assigned the O2 Gold 
breathing device that had been pre-coded by the manufacturer prior to the study; 50% 
assigned to the active trial first, and 50% assigned to the placebo trial first. The cross-over 
design of the study is clarified in the schematic representation given in Table 3.1. 
 







     28-day 
intervention 
period 
    




















3.3  Testing Procedure 
On three occasions participants were required to present themselves to the Exercise 
Laboratory in the Division of Human Physiology at the University of KwaZulu-Natal, 
Westville Campus. Before the first 28-day intervention period participants reported to the 
laboratory. After studying the information sheet (Appendix B), consent forms were 
completed by each athlete (Appendix C). Thereafter a medical questionnaire (Appendix D) 
as well as baseline questionnaires (Appendix E) which provided information regarding their 
training history, their dietary intakes, mileage/racing experience as well as other sporting 
endeavours) were completed. Basic anthropometric measures including stature (cm), body 
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mass (kg; in running shorts without shoes), waist circumference (measured at the mid-point 
between the lowest rib and the top of the illiac crest) and seven-site skinfold measurements 
including the triceps, chest, mid axilla, suprailiac, subscapular, abdominal and thigh skinfold 
thickness, were taken. Percentage subcutaneous body fat was calculated using the Jackson 
and Pollock (1978) formula. 
Dynamic resting lung function including FVC, FEV1, FVC/FEV1 and FIV1 was determined 
using a Jaeger Mastercope Flowmate Spirometer (Wuerzburg, Germany), as seen in Figure 
3.1 below. All participants underwent medical screening conducted by a general practitioner 
in order to assess their general health, musculo-skeletal status and to rule out the presence of 
any clinical condition/s that may have prevented full participation in the trial. A 4mL venous 
blood sample was then taken. 
Figure 3.1  Lung Function Testing using a Jaeger Mastercope Flowmate Spirometer 
 
The Oxygen Pro Analyser (Cardinal Health, Hoechberg, Germany) was used to measure 
metabolic and respiratory responses before and during exercise. After verification of ambient 
air conditions as determined by the integrated Ambient Unit, automatic calibration of the 
volume sensor was conducted according to manufacturer’s recommendations (Cardinal 
Health, Hoechberg, Germany). Gas analysers were calibrated using room air and a 2-litre gas 
cylinder containing 16% O2 and 5% CO2 in nitrogen (Cardinal Health, Hoechberg, 
Germany).   
 
After entering the participant details (including body mass) into the computer, a heart rate 






connected to a disinfected triple V transducer and twin tube, were fitted. Exhaled respiratory 
gas analysis was then performed using Triple V sensors to detect the volume of expired air, 
and an aliqout thereof was fed into the gas analysers. A pulse oximeter (Oxypal, OLV-2700, 
Nihon Kohden, Japan) was used to provide a continuous non-invasive measurement of O2 
saturation of the arterial blood before and during the test. 
 
Prior to starting the exercise trials, baseline data (including heart rate, blood pressure, 
oxygen saturation, VE and VO2) were recorded while the participant was comfortably seated 










Figure 3.2  Baseline Measures Conducted before the start of the Maximal Exercise Test  
 
 
Participants were then introduced to the motor 
driven treadmill (Powerjog GX100, Sport 
Engineering Limited, Birmingham, England) on 
which all VO2max testing was conducted. They 
completed a five minute warm-up at a speed of 12 
km.hr
-1
 with no incline.  Thereafter the speed 
remained constant (at 12 km.hr
-1
) while the 
gradient increased to an initial 2% in the first 
minute and a further 1% each minute until the test 
was terminated.   
 




 Continuous monitoring of heart rate and oxygen saturation occurred throughout the test, as 
depicted in Figure 3.3 above, and a 10 point Borg scale was used to quantify subjective rate 
of perceived exertion (Borg. 1982).  
 
The test was terminated when participants had reached three of the following: (i) RPE of > 
8.0 (ii) an RER of 1.15 or greater (iii) estimated heart rate maximum (iv) an apparent VO2 
plateau despite a further increase in workload on the treadmill.  
 
Immediately post-test systolic and diastolic blood pressure was measured, as well as a 60 
second and 120 second post exercise HR recording, while participants were seated on a 
















3.4  Active and Placebo Interventions 
Participants were required to use each of the magnetic breathing devices a minimum of 30 
times daily for the 28-day duration of each intervention. Inhalations were to be taken daily, 
either at half-hour intervals or at the end of the day with two minute breaks between 
inhalations, as stipulated by the manufacturer of the device. Figure 3.5 presents a detailed 




















Figure 3.5  Manufacturer’s recommendations for use of the O2 Gold device 
 
3.5  Quantification of Training Status 
Participants were requested to record their daily usage of the device, training volume and 
intensity on a daily basis (Appendix F). An index of their training status (Ts index) based on 
the total amount of training that was done during each of the 28 day trials was computed. 
This was determined from the sum of the number of minutes spent training at high (0.8), 
medium (0.5) and low (0.2) intensity for each day of the week and then averaged over the 4 
weeks. 
 
Ts index = ∑ time (0.2) + ∑ time (0.5) + ∑ time (0.8)/4 
 
Examples of Ts index, ranging from 1.42 - 26.73, are provided in Appendix G 
Exhale maximally 
Place the mouth over the mouthpiece 
and inhale maximally 
 
Hold breath as long as possible 
 
Exhale and remove the mouthpiece 





3.6  Processing of Blood Samples 
Four mL of whole venous blood was collected in vacutainer tubes containing K3 - ethylene 
diaminetetra-acetic acid (EDTA) and transported to a commercial pathology laboratory 
(Ampath Laboratories, Westridge, Durban) for the assessment of full blood count (FBC).   
FBC and differential leukocyte and platelet counts were determined on the EDTA treated 
specimens using standard haematological procedures on an automated STKS model (Coulter 
Electronics Inc., Hialeah, Florida, USA).    
 
A further 4mL sample was collected in pre-cooled EDTA tubes and immediately centrifuged 
at 3000rpm for five minutes, while serum collection vacutainer tubes were used for the 
collection of the third 4mL sample which was allowed to clot at ambient temperature after 
which the serum was separated by centrifugation at 3000 rpm for four minutes. Aliquots of 
0.5mL of plasma and serum were snap-frozen in liquid nitrogen until transferred to an ultra-
freezer at -80
o
 Celsius for storage in the Department of Human Physiology for later ELISA 
analysis of the concentration of plasma IL-3, determination of serum EPO concentrations 
and serum osmolality. 
 
After noting a trend of decreased post-exercise blood pressure following numerous trials 
during the study, additional post-exercise samples were collected into pre-cooled EDTA 
tubes from the last few participants tested. They were immediately centrifuged at 3000rpm 
for five minutes. Aliquots of 0.5mL of plasma were snap-frozen in liquid nitrogen until 
transferred to an ultra-freezer at -80
o
C for later indirect determination of nitric oxide from 
the concentration of nitrate and nitrite in these samples as well as the pre-exercise-samples 
obtained before the exercise-test at baseline. 
 
3.7  Biochemical Analysis of Blood Samples 
 
3.7.1  Plasma IL-3 Concentration 
An in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human 
IL-3 in serum, plasma and cell culture supernatants was conducted using IL-3 human ELISA 




The stock standard was prepared by adding 400µl assay diluent into a vial containing IL-3 
standard. Seven serial dilutions were prepared by adding assay diluent to the stock standard 
as shown in Figure 3.5. 
 
Figure 3.6  Serial Dilution of Standard 
 
A 96- well plate was coated with an antibody specific for human IL-3 standards and blood 
plasma samples were pipetted into wells and IL-3 present in the samples was bound to the 
wells by the immobilized antibody. The wells were washed and biotinylated anti-Human IL-
3 antibody was added. After washing away unbound biotinylated antibody, HRP-conjugated 
Streptavidin was pipetted to the wells. The wells were again washed. A TMB substrate 
solution was added to the wells and colour developed in proportion to the amount of IL-3 
bound. The stop solution changed the colour from blue to yellow and the intensity of the 
colour was measured at 450nm.   
 
3.7.2  Erythopoietin Concentration 
Serum samples were selected from a subsample of athletes for the assessment of EPO. A 
Pathology Laboratory (Ampath Laboratories, Westridge, Durban) determined serum EPO 
concentration using a commercial radioimmunoassay. 
 
3.7.3  Nitric Oxide Determination 
The principle of this assay was reduction of nitrate by vanadium (III) combined with 
detection by the acidic Griess reaction. NO has a short half life and exists at low 
concentrations thus detection is impractical. The stable metabolites, nitrites and nitrates can 
be used as a measure. Thus NO concentration is indirectly determined by nitrites, formed by 
auto-oxidation of NO in aqueous solutions and nitrates, formed by reaction of NO with 
superoxide or oxyhaemoglobin. This assay was sensitive to 0.5µM NO3. Standards were 
prepared by dissolving 6.06mg of sodium nitrate in dH2O. Eight serial dilutions were 
prepared from 0-200µM. 50µl of serum blood sample was pipetted into a well of a 96 well 
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plate in triplicate and 50µl of VCl3 followed by 25µl of sulfanilamide and N-1-napthyl 
ethylenediamine dihydrochloride were rapidly added to each well. The plate was then was 
then incubated for 30-45min (in the dark). Absorbance was measured at 540nm with a 
reference of 690nm.  
 
3.8  Uncoding and Final Feedback 
After all testing procedures for both trials were completed by the participants, the coding of 
the devices was revealed to the researchers by the manufacturer. A comprehensive feedback 
report was compiled for each participant (examples given in Appendix H). After the device 
compliance was established and training status during the two separate 28-day trial periods 
was calculated using the Ts index, described on page 33, the necessary exclusion of 
additional non-compliant participants took place and the final sample size (n=10) was 
confirmed.  
 
3.9  Statistical Analyses  
Data were expressed as mean (±SD and were analysed with GraphPad Prism 5 Software 
(Version 5.01, 2007).  Level of significance was set at p=0.05.  
 
Paired t-tests were used when comparisons of the post-active and post-placebo trials was 
required. One-way analysis of variance (ANOVA) with a Bonferroni correction to establish the 
exact location of the differences, was used to determine whether the difference between the 
means of baseline, post-active and post-placebo trials were significant or not. 
 
Pearson’s Product Moment Co-efficient of Correlation was used to determine whether the 









Eighteen athletes who met all inclusion criteria initially enrolled for the trial and completed 
the baseline assessment. Of these only thirteen completed both active and placebo trials. Five 
participants withdrew, three due to personal reasons, one due to medical reasons and another 
due to a knee injury. 
 
When analysing the training records and the compliance of the participants’ use of the 
magnetic breathing device (Appendix F), an additional three participants who had completed 
both sets of post-trial tests needed to be excluded from the study.  This was necessary as 
variation in training status, as revealed by computation of their Ts index (Appendix G) and 
irregular/inadequate use of the magnetic device, may have confounded their results. 
 
According to the data provided by participants, ten participants therefore complied with all 
aspects of the study. Uncoding of the devices of the fully compliant participants revealed 
that seven of the final sample (n=10) completed the active trial first and three completed the 
placebo trial first. 
 
4.1  Participants’ Characteristics 
The ten participants who complied with all aspects of the study were aged between 27 and 
40 (mean: 32.3±4.9 yr) with a mean stature (cm) of 175.8±7.7. They included elite 
endurance athletes who participated in a variety of endurance events including a combination 
of running, paddling and cycling e.g. Dusi Canoe Marathon (n=8) as well as a serious 
participant in gymnasium training (n=1) and a recreational runner (n=1).  
 
No participants reported deviation from usual regular dietary practices, vegetarianism, or 
acknowledgement of the use of iron supplementation or any form of ergogenic aid, during 
the course of the 10 week study. 
 
Further mean (± SD) baseline physical characteristics of these participants are provided in 
Table 4.1. No statistically significant difference was found in mean (±SD) data recorded 
between baseline data and after the active and placebo trials (p>0.05). 
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Table 4.1  Mean (± SD) and range of baseline characteristics of the participants who 





Mean (SD); Range 
         After placebo trial 
 
         Mean (SD); Range 
 
After active trial 
 
Mean (SD); Range  
Mass (kg) 74.7 (4.7); 65.6-82.7            74.6 (4.3); 67.3-81.5 74.6 (3.9); 67.3-80.9 
% body fat * 13.3 (5.6); 6.1-24.1           12.7 (5.6); 6.4-24.6 12.8 (5.4); 6.0-23.7 
RHR (bpm) 56.0 (5.8); 48-66           49.4 (4.9); 40-61 52.4 (12.8); 40-84 
SBP (mmHg) 124.2 (8.1); 112-142           122.0 (5.3); 112-128 123.6 (5.8); 114-132 
DBP (mmHg) 68.0 (8.7); 50-80           69.8 (7.9); 60-86 65.0 (5.8); 60-78 
* Derived from the sum of triceps, chest, mid axilla, suprailiac, subscapular, abdominal and thigh skinfold 
thickness; RHR: Resting heart rate, SBP: Systolic blood pressure, DBP: Diastolic blood pressure 
 
 
Results of the quantification of the training status index (Ts) while using the active and 
placebo devices are shown in Table 4.2. The mean (±SD) was not statistical significant 
between the two trials (paired t test; p > 0.05).  
 
Table 4.2  Mean ± SD training status index (Ts) while on active and placebo devices 
 
Characteristic  After placebo trial After active trial 
 
Mean 9.94 11.51  
SD ±6.07 ±6.66  
 
4.2  Lung Function  
With regard to the mean (± SD) and range of lung function shown in Table 4.3, FVC was 
consistently in excess of the reference range for non-athletic individuals of the specified age, 
gender and height. Only one participant presented with an FEV1/FVC ratio of <0.80, 
indicating the presence of possible minor obstruction to air flow.  
 
Table 4.3  Mean (± SD) and range of lung function of the participants who complied with all 







Mean (SD); Range 
      After placebo trial 
 
      Mean (SD); Range 
 
After active trial 
 
Mean (SD); Range  
FVC (L/min) 5.3 (0.7); 4.0-6.5        5.5 (0.8); 4.2-6.7 5.4 (0.7); 4.0-6.3 
FEV1 (L/min) 4.4 (0.5); 3.5-5.1        4.3 (0.5); 3.5-5.1 4.4 (0.5); 3.4-5.1 
FEV1/FVC 0.8 (0.1); 0.7-1.0        0.8 (0.1); 0.7-0.9 0.8 (0.1); 0.7-0.9 
FIVC (L/min) 5.4 (0.7); 4.4-6.6        5.6 (0.8); 4.3-6.9 5.5 (0.6); 4.2-6.3 
BHT  77.4 (28.6); 48-132        91.4 (29.8); 45-144 93.3 (31.6); 60-148 
FVC: Forced Vital Capacity, FEV1: Forced Expiratory Volume in 1 Sec, FVC/FEV1: Forced Expiratory 
Volume:  Forced Vital Capacity in 1 Sec, FIVC: Forced Inspiratory Capacity, BHT: Breath holding Time 
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Although one-way ANOVA revealed that the difference between the mean (±SD) of the tests 
of dynamic lung function conducted at the three trials, was not statistically significant 
(p>0.05), six (60%) participants recorded an improvement (vs. baseline) in FVC and five 
(50%) in FIVC following the active trial. The mean (±SD) of the FVC of the six positive 
responders was significantly greater than baseline (p = 0.038). These results are graphically 











Figure 4.1  Graphical representation of results of lung spirometry in the positive responders 
(FVC, n=6 and FIVC, n=5) Data presented as mean (±SD) * p<0.05, paired students t test 
 
4.3  Maximal Exercise Test 
The mean (± SD) and range of the selected data obtained from the maximal exercise test, is 
provided in Table 4.4. The tests ranged in duration from 8 to 17 minutes. It was confirmed 
by one-way ANOVA that use of the magnetic breathing device did not optimize mean 
workload on the treadmill or final mean running time obtained in the test, during active 
and/or placebo trials (p>0.05). However five (50%) participants recorded an improvement 
(vs. placebo) in maximum running time and hence peak power output following the active 
trial. The mean (± SD) improvements of this subsample of positive responders (n=5) was 
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Table 4.4  Mean (± SD) and range of  results of maximal exercise test of the participants 
who complied with all aspects of the trial (n =10)
 
HR: Heart rate, VE: Minute ventilation, RPE: Rating of perceived exertion, TV: Tidal volume, BF: Breathing 
frequency, RER: Respiratory exchange ratio;* n=8,  
 
In terms of submaximal physiological response during the last 15 seconds of the 8
th
 minute 
of the incremental protocol used in the maximal exercise test, an improvement (vs. placebo) 
in submaximal heart rate and O2 saturation was documented in four (40%) and three (30%) 
of the participants, respectively. One-way ANOVA however revealed no difference in terms 
of mean (± SD) submaximal heart rate and O2 saturation during this stage of the test in the 
complete sample (n=10, p= 0.69; 0.94). This lack of significance in the differences between 
trials was also apparent in the positive responders (n= 4,3; p = 0.098, 0.12)  
 
No significant improvements in mean or individual maximum minute ventilation, tidal 
volume and breathing frequency (p>0.05) were noted use of the active device. Although 





Mean (SD); Range 
After placebo trial 
 
 Mean (SD); Range 
 
After active trial 
 
Mean (SD); Range  
SUBMAXIMAL  
(During the last 15 seconds 8
th
 minute of the exercise test) 
    
HR (bpm) 165.4 (12.9); 144-188  160.7 (12.1); 144-180 161.4 (14.5); 138-182 




9.5 (2.9); 4.0-13  9.6 (3.1); 5-14 9.8 (3.1); 5-13 
Running Time 
(min) 
8.6 (2.8); 3.3-12  8.6 (3.0); 3.7-12.1 7.8 (4.1); 3.6-12.1 
HR (bpm) 184.0 (9.0); 169-194  183.4 (6.6); 168-191  182.4 (9.1); 164-195 
O2 saturation (%) 90.4 (2.2); 87-93  91.0 (2.9); 85-95 90.1 (3.4); 85-95 
RPE  8.8 (1.4); 6-10  9.1 (1.7); 5-10 9.5 (1.0); 7-10 
VE (L.min
-1
) 150.7 (18.5); 130-192  155.4 (16.7); 128-189 154.8 (15.1); 133-186 
TV (L) 3.1 (0.4); 2.6-3.7  3.2 (0.4); 2.6-4.0 3.2 (0.4); 2.6-3..8 
BF (breaths.min
-1
) 50.1 (8.0); 39-61  50.1 (8.0); 41-62 50.1 (7.9); 40-64 
VO2 (mL.min
-1






) 65.3 (8.1); 55-78.5 67.3 (7.8); 58-80.4 66.1 (9.1); 55.6-81.5 
  POST TEST 
60 sec HR (bpm) 149.2 (10.9); 130-162 143.9 (10.8); 130-162 145.6 (11.2); 128-165 
120sec HR (bpm)* 126.3 (10.3): 109-139 116.4 (10.7); 101-131  119.3 (13.3); 102-144 
SBP (mmHg) 171.4 (17.9); 140-200 185.2 (12.4); 162-202 179.3 (9.3); 164-192 




after use of the active or placebo devices, when compared to baseline testing, five (50%) 
participants recorded small improvements (vs. placebo) in absolute VO2 max following the 
active trial. These improvements which averaged 6.5% were however not great enough to 
create a statistically significant difference in the mean (p = 0.37). 
 
Regarding post test recovery, neither mean (± SD) post-test heart rate recovery at the 60 and 
120 second time-points or post-test diastolic blood pressure, were significantly lower in the 
entire sample  (n=10).  There was however a significant drop in HR recovery at the 120 
second time point in four (40%) of the sample (p = 0.033) and in DBP in five (50%) 
individual participants following the active trial (p = 0.086). As is shown in Table 4.5, pre-
post treadmill running blood samples were obtained from two of these participants and 
showed an increase nitric oxide concentration in both when on the active device. 
 
Table 4.5  Individual and mean serum Nitric Oxide concentrations (µM) determined from 
plasma nitrate and nitrite concentration in a subsample (n=2) in whom lower post-trial 
diastolic blood pressure was recorded after being on the active device. 
 
Participant Placebo  Active  
11  58.74 92.12 




± 6.28  
93.53  
± 1.99  
SD: Standard deviation 
 
4.4  Red Blood Cell Indices 
Mean (± SD) and range of red blood cell indices of the participants who complied with all 
aspects of the trial (n =10), are shown in Table 4.6. The findings of a lack of significance in 
the difference between mean Hct and Hb concentration were paralleled by an absence of 
changes in the mean cell volume of the red blood cells. One-way ANOVA confirmed the 
absence of a statistical significance in both mean RBC and Hb (p>0.05). However when data 
from individual participants were analysed, six (60%) of the sample presented with 
significant increases in RBC count (vs. placebo; p = 0.029) and five (50%) with a significant 








Table 4.6  Mean (± SD) and range of red blood cell indices of the participants who complied 
with all aspects of the trial (n =10) 
Characteristic  Baseline 
 
Mean (SD); Range 
       After    placebo trial 
 
        Mean (SD); Range 
 
 After active trial 
 
Mean (SD); Range  
Hb (g/dl) 16.6 (0.3); 15.2-16.1         15.1 (0.8); 13.9-16.4  15.5 (0.8); 13.9-16.6 
RBC( 10
12
/L) 5.0 (0.1); 4.9-5.2         4.9 (0.3); 4.6-5.4  5.0 (0.3); 4.7-5.3 
Hct (%) 46.1 (1.0); 44.4-47.4         44.3 (2.1); 41.1-47.7  45.5 (2.0); 42.1-48.4 
MCV (fL) 91.5 (2.5); 88.6-96.3         91.3 (2.2); 89.1-96.5  91.1 (2.5); 88.6-96.6 
MCH (pg) 30.2 (3.0); 21.8-32.5         31.1 (1.2); 29.8-33.8  30.9 (1.2); 29.5-33.5 
MCHC (g/dL) 33.9 (0.5); 33.0-34.3         34.1 (0.7); 33.2-35.2  33.9 (0.6); 32.9-34.7 
RDW (%) 13.0 (0.3); 12.7-13.6         13.1 (0.3); 12.5-13.6  13.0 (0.3); 12.6-13.5 
Hb: Haemoglobin, RBC: Red blood cell, Hct: Haematocrit, MCV: Mean cell volume, MCH: Mean cell 
haemoglobin,  MCHC: Mean cell haemoglobin concentration  RDW: Red cell distribution width 
 
4.5   VO2 Max vs. Red Blood Cell Count 
The relationship between the change in absolute VO2max and change in RBC in each 
participant following placebo and active trials is presented in Figure 4.2. This revealed 
positive, linear correlation (r = 0.68) which is statistically significant (p = 0.029).  
   
 
Figure 4.2  The association between change in absolute VO2max and change in RBC count 
following active and placebo trials in the complete sample (n=10). * Pearson’s Product 
Moment Co-efficient of Correlation 
 
4.6  Serum EPO  
The individual serum EPO concentration following active and placebo trials for a subsample 
of 7 participants, is given in Table 4.7. The mean (±SD) was not significantly improved 
(p=0.13; paired students t-test) with the use of the active breathing device in this subsample. 
As is shown in Figure 4.3, Pearson’s product moment co-efficient of correlation also did not 
∆ absolute  
 VO2max  
(L/min) 
 
∆ RBC  
 count  
(g/dL) 
 





confirm a statistically significant correlation between the change in serum EPO 
concentration and the change in red blood cell count (r
 
= 0.69; p<0.05) following active and 
placebo trials. 
 
Table 4.7  Individual and mean (± SD) serum EPO (mLU.mL
-1
) concentration following 
active and placebo trials, taken from a subsample of participants (n=7)  
 
Participant No. After placebo trial  After active trial 
1 45.5  58.9 
5 12.9  11.8 
6 39.1  64.0 
8 10.2    5.7 
10   2.3    5.4 
11 114  136 
13   2.9    0.7 
Mean 24.2  29.8 












Figure 4.3  The association between change in serum EPO concentration and change in 
RBC count following active and placebo trials. * Pearson’s Product Moment Co-efficient of 
Correlation 
 
4.7  Plasma IL-3 Concentrations 
Although individual plasma IL-3 concentrations increased following the active trial in four 
(40%) of the study sample, one-way ANOVA revealed that there was no significant 
difference in plasma IL-3 concentration between baseline and active and placebo 
interventions (p>0.05). Mean (± SD) plasma IL-3 concentrations at baseline and following 
active and placebo trials (n=10) are shown in Figure 4.4 




















































Figure 4.4  Mean (±SD) plasma IL-3 concentration (pg.mL-1), at baseline and following 
active and placebo trials (n=10) 
 
4.8  Integrated Physiological Profile of Positive Responders 
When the individual profile of each of the five participants in whom either an improvement 
in absolute VO2max or peak power output on the treadmill was achieved during the maximal 
exercise test following the active trial, is analysed, this corresponds with an increase in RBC 
concentration in 100% of the group and an increase in HB concentration in 80% of the 
group. Furthermore, submaximal heart rate in the last 15 seconds of the 8
th
 minute of the test 
as well as 2 minute post-test HR , also improved in 80% (n=4) of the sample. The overall 
profile of these positive responders (n=5) is presented in Table 4.8.   
 
Table 4.8  Overall profile of positive responders to improvement in absolute VO2max or 
peak power output on the treadmill (n=5) 




























          
1 + - + + + + - - + 
5 + + + + + + + + - 
6 + + - - + + + + + 
8 - + + + + + + + - 




4.9  Conclusion 
Statistically significant differences between the active, placebo and baseline trials were not 
apparent in any of the reported measures when expressed as mean ± SD of the completed 
sample (n=10). However following 28 days of use of the magnetic device, 60% of the 
sample presented with a statistically significant improvement in mean ± SD FVC and RBC 
count (p = 0.038; 0.029)and 40% with significantly improved mean ± SD peak power output 











DISCUSSION OF RESULTS 
 
 
5.1  Introduction 
While the restricted sample size may be regarded as a limitation of this work, this study 
required an exceptional amount of commitment from each participant. They were expected 
to use the device 30 times a day, maintain their usual dietary intake and keep their training 
status consistent over the course of the study. This led to the decrease in sample size from 
eighteen to ten participants over the 10 week duration of the study.  
 
Only thirteen participants completed both active and placebo trials as well as the three 
assessments. Four athletes presented with influenza and/or upper respiratory tract infection 
symptoms. In addition the time of year was not optimal for the majority of these participants 
who were endurance athletes as it is generally their off season/ base training period over the 
winter months. Therefore it was difficult encouraging them to maintain their initial high 
training volume. After the computation of the Ts index of the participants (Table 4.2), three 
additional participants therefore had to be excluded from the study as their training was 
inconsistent or they had been ill for an extended period of time, thus decreasing both training 
and compliance in using the device. The final sample (n=10), although limited in size, was 
therefore restricted only to individuals who had reported adequate compliance with the 
inclusion criteria of the study. It is felt that this stringent attention to control possible 
confounding influences was an important strength of the study.  
 
Another strength of the study was the cross-over design (Table 3.1) which was preceded by 
baseline testing. This resulted in each athlete acting as their own control and the sequence of 
trials varying equally within the original sample (n=18). The intention was that any possible 
carry-over effect in those who first used the active device would have been apparent when 
placebo trial results were compared to the results of the baseline testing. Provision was made 
for this by the use of a one-way ANOVA followed by a Bonferroni post hoc test in the 




5.2  Participant  Characteristics and Quantification of Training 
The mean ± SD percentage body fat (12.8 ± 5.4), resting heart rates (52.4 ± 12.8 bpm) and 
diastolic blood pressures (65.0 ± 5.8 mmHg) of the participants (Table 4.1) confirmed that 
they were in elite sporting condition throughout the entire duration of the study. The athletes 
had above normal lung function with a mean ± SD FVC of 5.4 ± 0.7 L.min
-1
 and FIVC 5.5 ± 
0.6 L.min
-1
. Statistical analysis also revealed that this condition did not change significantly 
over the 10 week period of the two trials.  
 
As this study focused on cardio-respiratory function, change in training status was one of the 
most important potential confounders of the results of this study. As discussed on page 33, a 
method was therefore devised in order to quantify the participants specific Ts while using the 
active and placebo devices. This showed lack of statistical significance in the difference 
between the amount of training done by the athletes during active and placebo trials 
(p>0.05), hence eliminating the possibility of changes in the fitness level of the athletes 
significantly confounding the results of the study.  
 
5.3  Lung Function  
The purpose of including a lung function test in the pre-post trial assessment was not to 
assess a possible effect of the magnetic influences of the device, but as a means of 
confirming compliance in the use of the device. It is well known that when air is inhaled 
through the device, resistance to airflow is created. This resistance is believed to increase the 
work of the diaphragm, the external intercostal and the interchondral part of the internal 
intercostal muscles during the inhalation and has been shown to enhance endurance exercise 
performance in both trained and untrained individuals (Boutellier et al., 1992; Splenger et 
al., 1998; Roberts, 2004; 2007). Although no significant pre-post trial difference was found 
in mean (±SD) FVC, FEV1 or FIVC of the sample (n=10; p>0.05), when individual results 
of the participants were studied independently of the mean (±SD), only 50% of the final 
sample (n=5) showed a significant improvement in FVC and FIVC (p = 0.038; p = 0.095) 
when using the active magnetic inhaler. This does not confirm the compliance of these 
athletes with device use throughout the entire duration of both trials, and raises a question 
regarding the ‘reported’ compliance in the remaining participants. For this reason, it was 
regarded as prudent to also focus on individual results and conduct statistical analyses of the 





5.4  Red Blood Cell Indices 
Although not yet proven, it has been hypothesised that the magnetic effect on erythrocytes, 
Hct and Hb concentrations could influence athletic performance by increasing the oxygen-
carrying capacity of the blood (Roberts et al., 2008). Zhernovoi et al. (2001) found that in 
some Hb molecules exposed to a magnetic field, the bond between nitrogen and iron atoms 
are disrupted, causing Hb activation. O2 may then be added to the free bond of the iron atom 
of activated Hb. The enhanced O2 carrying capacity of blood may be explained by the 
binding of two O2 molecules to the iron atom of Hb in the presence of a magnetic field, 
forming bioxyhaemoglobin. Although this was confirmed in an unpublished pilot study 
conducted on 7 participants by Drs Craig Roberts and Bruce Biccard (Roberts, 2004), which 
showed a 0.9% improvement in the oxyhaemoglobin concentration from an average of 
94.4% to 95.3% after four weeks using the Therahaler magnetic breathing device (p = 
0.0516), the findings of this study did not lend support to this possibility. 
 
As the non-invasive measurement of oxyhaemoglobin concentration using pulse-oximetry 
has many limitations (Plummer, 1995) and the use of an arterial blood sample was regarded 
as too invasive a procedure to use on the athletes prior to a maximal exercise test, no 
specific, sensitive measure of oxyhaemoglobin concentration was obtained in this trial and 
the haematological assessment in this trial was restricted to venous blood sampling.  
 
The mean (±SD) and range of both RBC and Hb concentrations showed no statistically 
significant improvement following the active trial. Although this finding which did not 
confirm previous findings of Chater et al. (2003), all of the positive responders in terms of 
VO2max and peak power output (n=5), did however present with statistically significant 
increases in RBC count (p=0.029) and Hb concentration (p=0.047). As these individuals 
also had improved lung function which confirmed their use of the device, the alternative 
hypothesis set at the onset of the study, that RBC indices would improve following use of 
the magnetic breathing device, cannot be rejected. The possibility of unacknowledged under-
compliance in usage of the device and the existence of non-responders in whom venous 
blood RBC and Hb concentrations do not rise with a small rise in oxyhaemoglobin 
concentrations, does however need to be acknowledged. 
 
In view of previous findings that RBC counts are increased following use of the device, 
focus was also placed on possible mechanisms in this trial.  Therefore the circulating 
49 
 
concentration of the hormone EPO and the haematopoietic growth factor, IL-3, were 
investigated.  However no significant differences were obtained in the means (±SD) between 
active and placebo trials or the association between pre-post change in serum EPO 
concentration and change in RBC count. Mean plasma IL-3 concentration also did not 
change, therefore a direct effect on the circulating concentration of EPO and IL-3 can be 
excluded as possible mechanism by which the O2 Gold may improve blood cell status.  
 
5.5  Maximal Exercise Test 
 
5.5.1  Peak Power Output and Exercise Time to Exhaustion  
One of the primary findings of the study was that although statistically significant 
improvement in mean peak power output (% gradient on the treadmill) and exercise time to 
exhaustion, as described previously by Roberts et al., (2008), was not confirmed in the 
complete sample (n=10), there were however five positive responders. Four of the five 
participants who showed a statistically significant increase in both peak power output and 
exercise time to exhaustion were the elite endurance athletes, thus suggesting that well 
trained endurance athletes are perhaps more responsive. 
 
A possible overriding confounder which cannot be overlooked, was the competitive nature 
of the participants and their intrinsic motivation to ‘push themselves’ to maximum capacity 
and better their performance during each consecutive test. While this may have played a part 
in their maximal performance, the cross-over design of the study was aimed at compensating 
for this possibility. Of further interest was the finding shown in Table 4.4, that there was no 
benefit associated with use of the magnetic breathing device (p >0.05) in terms of their 
perception of effort at the same work load, as RPE was not reduced after using the active 
breathing device. 
 
5.5.2  Response to Submaximal Exercise 
Submaximal heart rate, recorded in the eighth minute on the maximal exercise test, also 
showed an improved in 40% of the participants when using the active devices, but the mean 
mean (±SD) of this subgroup did not reach statistical significance (p = 0.098). The finding 
of this study does therefore not confirm the early pilot work conducted by Ryan in 2003 












Higher submaximal O2 saturation, based on pulse oximetry, was only documented in 30% of 
the participants.  The insignificant difference in users of the active breathing device obtained 
from both the results of the ANOVA analyses and analysis of the individual positive 
responders, therefore do not support those of Biccard (2005). Although a special effort was 
made to overcome the limitation of considerable variability with hand movements during 
treadmill running (Plummer, 1995) by only recording stable readings during the last 15 
seconds of each workload, pulse oximetry does also provide a relatively gross estimation of 
saturation of Hb with O2 (percentages in whole numbers). Sole reliance on this technique for 
the measurement of O2 saturation must therefore be acknowledged as a limitation of the 
study. 
 
5.5.3  VO2 max  
As VO2 max is a function of numerous cardio-respiratory processes including lung 
inspiratory and pulmonary diffusing capacity, cardiac output, oxygen carrying capacity as 
well as uptake of oxygen at the level of skeletal muscle (Bassett and Howley, 1999), this 
assessment was a major focus of this study.  Interpretation of the findings were only based 
on absolute VO2 max recordings (L.min
-1
) as the relative VO2 max is reliant on a change in 
body mass over the 10 week period of the trial. 
 
One of the most important findings of this study was that absolute VO2 max only improved 
in 40% of the sample. The magnitude of the mean improvement (6.5%) in this subsample 
(n=4) was however not sufficient to result in a statistically significant change at the 0.05 
level of significance. Furthermore, as is seen in Table 4.8, this was not accompanied by an 
improved peak power output and running time on the treadmill in the each of the 
participants. The practical significance of these findings for endurance athletes is therefore to 
be questioned. 
 
A further interesting and important observation is that in the four positive responders, the 
improvement in absolute VO2 max was accompanied by an increase in RBC count in each of 
the participants and in Hb concentration in four of the participants (Table 4.8).  This was also 
supported by the positive correlation between VO2 max and RBC in the complete sample 
(Table 4.2). The findings therefore lend support to the premise that central factors may affect 





5.5.4  Post Maximal Exercise Test Heart Rate and DBP  
In this study mean (±SD) and range of recovery heart rate, both 60 and 120 seconds post-test 
however showed no statistically significant improvement in both active and placebo trials. 
Upon analysis of individual results, 40% of the participants showed an improvement in 120 
second post maximal exercise test HR recovery when using the active device. The mean 
(±SD) improvement was significant and confirms the hypothesis of Philpott (1998) and the 
findings of Jehenson et al. (1998) following the exposure to the high intensity SMF, as well 
as those of Ryan (2007). On the other hand, the absence in improvement in non-responders, 
although possibly due to lesser compliance in use of the device, may lend support to the 
findings of Hipman (2002). As the sample size in this study was small, further work is 
therefore required in order to clarify this question.  
 
Five participants presented with a lower post-test DBP following use of the active device 
confirming the findings of Okan and Ohkubo (2001). It is well accepted that the synthesis of 
nitric oxide by vascular endothelium is responsible for the vasodilator tone that is essential 
for the regulation of blood pressure (Moncada and Higgs, 1993). Pre-post treadmill running 
venous blood samples were taken and analysed for nitric oxide concentration from two of the 
participants during the later phases of the study. Interestingly in both of these participants 
who also presented with lower post-test DBP, an increase in nitric oxide concentration was 
found in the post exercise test samples following the use of the active device (Table 4.5). 
This once again confirms the findings of Okan and Ohkubo (2001; 2003; 2005) and presents 
a direction for further research on humans. Whether the well described post exercise 
hypotension (Noakes, 2001) is exacerbated by the use of the magnetic breathing device, is an 
important question requiring further examination.  
 
5.5.5  Conclusion  
When individual profiles of the five participants who presented with either an improvement 
in absolute VO2max and/or peak power output on the treadmill are taken into account, a 
100% presented with an improvement in RBC concentration and 80% with an improvement 
in Hb concentration after use of the active O2 Gold device. The remaining 20% presented 
with an equal Hb concentration after both active and placebo trials (Table 4.8).  Lack of 
compliance in device use may account for the remaining 20% of the results. Hence further 






However the practical value of a 6.5 % improvement in absolute VO2 max to the athletes is 
to be questioned as this cannot compensate for or override the value of a well designed and 
implemented schedule of training which is known to increase VO2max and peak treadmill 











CONCLUSIONS AND DIRECTIONS FOR FURTHER RESEARCH 
 
Every attempt was made to monitor participants throughout the entire duration of the trial in 
terms of their compliance with the device use, maintenance of a consistent training status 
and a balanced diet and refraining from the use of ergogenic aids. However in a study 
involving human participants which requires an intervention which is so reliant on the 
truthfulness of the participants in terms of their use of the devices over such a prolonged 
period, the possibility of latent under-compliance is always a reality. Hence a deeper look at 
the ‘positive’ responders was considered appropriate. Positive effects on cardio-respiratory 
function as a result of the constant use of a magnetic breathing device was verified in 50% of 
the participants. 
 
According to the individual results of the five positive responders, the alternative hypothesis 
that the 1500G O2 Gold magnetic breathing device will improve peak power output and 
maximal running time on the treadmill, pre-exercise test respiratory function, RBC and  Hb 
concentrations and Hct of endurance athletes during a maximal exercise test, therefore 
cannot be rejected. The null hypothesis that twenty-eight days of regular use of the 1500G 
O2 Gold magnetic breathing device will not affect absolute and relative maximum oxygen 
consumption (VO2 max) , RPE, HR, VE, respiratory exchange ratio (RER) and O2 saturation 
at the workload at which VO2 max was reached, submaximal minute ventilation (VE, 1/min), 
absolute O2 uptake (VO2, L/min), heart rate (HR), rating of perceived exertion (RPE), and O2 
saturation, resting circulating IL-3 and EPO, is accepted. 
 
In order to exclude the possibility of Type 2 error, future research should include examining 
the effects of the O2 Gold on a larger sample size. However because of the difficulty in 
ensuring device usage and maintenance of training status and other externally related 
practices including diet, this may not be practical. Therefore further work needs to firstly 
focus on validation of the device usage and control of all possible confounders. Furthermore 
the effect of the O2 Gold should be determined in less well trained non-endurance athletes 
and the long term effects of the O2 Gold should also be examined. Further investigation of 
the preliminary observation of changes in markers of nitric oxide concentration associated 
54 
 









Albouaini, K., Egred, M., Alahmar, A., Wright, D. 2007. Cardiopulmonary exercise testing 
and its application. Postgrad Med. J. 83: 675-682.  
 
Åstrand, P. 1952. Experimental studies of physical working capacity in relation to sex and 
age. Copenhagen. Ejnar Munksgaard. 23-27. 
 
American College  of Sports Medicine. 2013. ACSM's Guidelines for Exercise Testing and 
Prescription, 9
th
 ed. Kerry O’Rourke, Baltimore. 
 
Baker-Price, L., Persinger, M. 1996. Weak but complex pulsed magnetic fields may reduce 
depression in following traumatic brain surgery. 83: 491-498. 
 
Bassett, D., Howley, E. 1997. Maximal oxygen uptake: “classical” versus “contemporary” 
viewpoints. Med. Sci. Sports Exerc. 29: 591– 603. 
 
Bassett, D., Howley, E. 1999. Limiting factors for maximum oxygen uptake and 
determinants of endurance performance. Med. Sci. Sports Exerc. 32: 70-84. 
 
Borg, G. 1982. Psychophysical bases of perceived exertion. Med. Sci. Sports Exercise. 14 
(5): 377-381. 
 
Boutellier, U., Buchel, R., Kundert, K., Splenger, C. 1992. The respiratory system as an 
exercise limiting factor in normal trained subjects. Eur. J. Appl. Physiol. 65: 347-353. 
 
Butariu, S., Galosi, L., Mihalas, G. 2009. Study of pulsed magnetic field action in 
posttraumatic peripheral nerve lesions of the upper extremity. Timisoara Med. J. 59(3).  
 
Cerretelli, P., Prampero, P. 1987. Gas exchange in exercise. The respiratory system, Vol. IV. 
American Physiology Society, Bethesta,  USA, pp 297-339.. 
 
Chakeres, D., Kangarlu, A., Boudoulas, H. 2003. Effect of static magnetic field exposure of 
up to 8 Tesla on sequential human vital sign measurements. J. Magn. Reson. Imaging. 18: 
346-352. 
 
Chater, S., Abdelmelek, H., Pequignot, J.,Garrel, C., Favier A., Sakly M., Rhouma K.B. 
2006 Effects of sub-acute exposure to static magnetic field on hematologic and biochemical 
parameters in pregnant rats.  Electromagn. Biol.Med. 25:135-144. 
 
Claude, B., An, P., Rice, T., Skinner, J., Wilmore, J., Gagnon, J., Perusse, L., Leon, A.,  Rao, 
D. 1999. Familial aggregation of VO2 max response to exercise training: results from the 
Heritage Family Study.  J. Appl. Physiol. 87 (3): 1003–1008. 
 
Colbert, A., Wahbeh, H., Harling, N., Connelly, E., Schiffke, H., Forsten, C., Gregory, W., 
Markov, M., Souder, J., Elmer, P., King. K. 2009. Static Magnetic Field Therapy: A Critical 




Costantino, C., Pogliacomi, F., Passera, F.,  Concari, G. 2007. Treatment of wrist and hand 
fractures with natural magnets: preliminary report. Acta Biomed. 78: 198-203. 
 
Daniels, J. 1985. A physiologist’s view of running economy. Med. Sci. Sports Exerc. 17: 
332–338. 
 
Daniels, J., Daniels, N. 1991. Running economy of elite male and female runners. Med. Sci. 
Sports Exerc. 24: 483–489. 
 
Dempsey, J., Hanson, P., Henderson. K. 1984. Exercise-induced arterial hypoxemia in 
healthy humans at sea-level. J. Physiol.335: 161-175. 
 
Dreyer, P., Schuster, T. 1984. Diamagnetism of human apo-, oxy-, and carbonmonoxy 
haemoglobin. Biochem. 23 (5): 865-872. 
 
Durney, C. ,Christensen, D. 1999.  Basic introduction to bioelectromagnetics. 2
nd
  Ed  CRC 
Press, New York. pp 1-8. 
 
Fagard, R. 1993. Physical fitness and blood pressure. J. Hypertens. 11 (5): S47–S52. 
 
Fagard, R. 1999. Physical activity in the prevention and treatment of hypertension in the 
obese. Med. Sci. Sports Exerc. 31: S613–S619. 
 
Ferretti, G., Antonutto, G., Denis, C., Hoppeler. H., Minetti, A., Narici, M.,  Desplanches, D. 
1997. The interplay of central and peripheral factors in limiting maximal 02 consumption in 
man after prolonged bed rest. J. Physiol. 501 (3): 677-686. 
 
Froelicher, V., Brammel, H., Davis, G., Noguera, I., Stewart, A., Lancaster, M. 1974. A 
comparison of three maximal treadmill exercise protocols. J. Appl. Physiol. 36: 720-725. 
 
George, M., Wassermann, E., Williams, W. 1996. Changes in mood and hormone levels 
after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. J. 
Neuropsychiatry Clin. Neurosci. 8: 172-180.  
 
Gerber, R. 2001.Vibrational Medicine. Bear and Company, Rochester, Vermont.  pp 297-
304. 
 
Giereke, A. 1999. Unpublished data. Correspondence: 24 Winkelspruit Rd, Winkelspruit, 
South Africa, 4145. 
 
Griffith, L., Roben, G., Rauckman, E. and Dreyer, B. 1984. Pharmacokinetics of nitroxide 
MRI contrast agents(Abstract). In: Society of Magnetic Resonance in Medicine, 2
nd
 Annual 
Meeting, San Francisco, CA, 1983,. Magnetic Resonance in Medicine 1:159-l 60. 
 







W. 2007. Erythropoietin regulations in humans under different 
environmental and experimental conditions. Respir. Physiol. and Neurobiol. 185: 287-297. 
 
Guyton, A., Hall, J. 2011. "Textbook of Medical Physiology”. Saunders, Pennsylvania, 12th 




Hawley, J., Myburgh, K., Noakes, T. 1995. Maximal oxygen consumption: A contemporary 
perspective. Lecture Material , B Sc Med Sci., University of Cape Town.   
 
Henry, S., Concannon, M., Yee, G. 2008. The effect of magnetic fields on wound healing: 
experimental study and review of the literature. Eplasty. 8: e40. Published online 2008 July 
25. PMCID:  PMC2490801 
 
Heywood, V. 1998. Advance Fitness Assessment & Exercise Prescription, 3rd Ed. Human 
Kinetics Publishers p. 48. 
 
Hill, A., Lupton, H. 1923. Muscular exercise, lactic acid, and the supply and utilization of 
oxygen. Q. J. Med. 16: 135–171. 
 
Hinman, M. 2002. Comparative effect of positive and negative static magnetic fields on 
heart rate and blood pressure in healthy adults. Clin. Rehabil. 16: 669–74. 
 
Hong, C. 1987. Static magnetic field influence on human nerve function. Arch. Phys. Med. 
Rehabil. 68: 162-164. 
 
Honig, C., Connett, R., Gayeski, T. 1992. O2 transport and it interaction with metabolism: a 
systems view of aerobic capacity. Med. Sci. Sports Exerc. 24: 47-53. 
 
Hyde, T., Gengenbach, M. 2007. Conservative Management of Sports Injuries. 2
nd
 ed; 
Sudbury, Mass. Jones & Bartlett, p 845. 
 
Issekutz, B., Rodahl, K. 1961. Respiratory quotient during exercise. J. Appl. Physiol. 16: 
606-616. 
 
Jehenson, P., Duboc, D., Lavergne, T. 1998. Change in human cardiac rhythm induced by a 
2-T static magnetic field. Radiology. 166: 227–30. 
 
Jelkmann, W. 2003. Erythropoietin: Molecular Biology and Clinical Use. Internal Medicine-
Tokyo-Japanese Society of Internal Medicine- 43.8: 649-659. 
 
Jennings, G. 1997. Exercise and blood pressure: walk, run or swim? J. Hypertens. 15: 567–9. 
 
Johnson, B., Babcock, M., Suman, O., Dempsey, J. 1993. Exercise induced diaphragmatic 
fatigue in healthy humans. J.Physiol. 460: 384-405. 
 
Khoromi, S., Blackman, M., Kingman, A., Patsalides, A., Matheny, L., Adams, S., Pilla, A., 
Max, M. 2007. Low intensity permanent magnets in the treatment of chronic lumbar 
radicular pain. J. Pain Symptom Manage. 34: 434-445. 
 
Kolata, G. 2002. Why Some People Won't Be Fit Despite Exercise. The New York Times. 
Retrieved 2007-07-17. 
 
Kouamé N., Nadeau A., Lacourcière Y. 1995. Effects of different training intensities on the 
cardiopulmonary baroreflex control of forearm vascular resistance in hypertensive subjects. 




Krcik, J. 2001. performance-enhancing substances: What athletes are using. Cleveland Clinic 
Journal of Medicine, 68 (4) 283-302 
 
Lee, R., Canaday, D., Doong, H. 1993. A review of the biological basis for the clinical 
application of electrical fields in soft tissue repair. J. Burn Care Rehabil. 14: 319-335. 
 
Laszlo, J., Gyires, K. 2009. 3-T homogeneous static magnetic field of a clinical MR 
significantly inhibits pain in mice. Life Sci. 84: 12-7. 
 
Londeree, B., Moeschberger, M. 1984. Influence of age and other factors on maximal heart 
rate. J. Cardiac Rehabil. 4: 44-49. 
 
Mador, M., Acevedo, F. 1991. Effect of respiratory muscle fatigue on subsequent exercise 
performance. J. Appl. Physiol. 70: 2059-2065. 
 
Mador, M., Magalanga, U., Rodis, A., Kufel, T. 1993. Diaphragmatic fatigue after exercise in 
healthy human subjects. Am. Rev. Respir. Dis. 146: 1571-1575. 
 
Man, D., Man, B., Plosker, H. 1999. The influence of permanent magnetic field therapy on 
wound healing in suction lipectomy patients: a double-blind study. Plast. Reconstr. Surg. 104: 
2261-2268. 
 
Mckay, J., Prato, F., Thomas, A. 2007. A Literature Review: The Effects of Magnetic Field 
Exposure on Blood Flow and Blood Vessels in the Microvasculature. Bioelectromagnetics. 28: 
81–98.  
 
Mengelkoch, L., Martin, D., Lawler, J. 1994. A review of the principles of pulse oximetry and 
accuracy of pulse oximeter estimates during exercise. Phys. Ther. 74: 40-49. 
 
Meredith, I., Friberg P., Jennings, G. 1991. Exercise training lowers resting renal but not 
cardiac sympathetic activity in human. Hypertension.18: 575–82. 
 
Miller, R. 1977. Methods of detecting and measuring healing energies. In Future Science, 
White JW, Kripner S, (Eds.): Anchor/Doubleday, Garden City, New York. pp 431-44. 
 
Mitchell, J., Sproule, B., Chapman, C. 1957. The physiological meaning of the maximal 
oxygen intake test. J  Clin Invest. 37(4): 538. 
 
Miura, S., Tashiro, E., Sakai, T. 1994. Urinary kallikrein activity is increased during the first 
few weeks of exercise training in essential hypertension. J. Hypertens. 12: 815–23. 
 
Mizushima, Y. 1975. Effects of magnetic field on inflammation. Experientia. 31: 1411-1412. 
 
Moncada, S., Higgs, A. 1993. The L-Arginine-Nitric Oxide Pathway. N. Engl. J. Med. 329: 
2002-2012. 
 
Morris, C., Skalak, T. 2008. Acute exposure to a moderate strength static magnetic field 
reduces edema formation in rats. Am. J. Physiol.-Heart Circuly Physiol. 294: H50-H57. 
 




Niekamp, K., McDaniel, J., Israel, H., Fontana, L., Villareal, D. and Weiss, E. 2012. The 
Role of Dietary PH on Maximal Respiratory Exchange ratio during Exercise Testing. JAm 
Diet Assoc, 100:  A56. 
 
Noakes, T. 1998. Maximal oxygen uptake: “classical” versus “contemporary” viewpoints: a 
rebuttal. Med. Sci. Sports Exerc. 30: 1381–1398. 
 
Noakes, T. 2001. Book: The Lore of Running. (4th edition) Oxford University Press, 
London.. ISBN 978-0-88011-438-7.  
 
Okano, H., Ohkubo, C. 2001. Modulatory effects of static magnetic fields on blood pressure 
in rabbits.  Bioelectromagnetics. 22: 408–418. 
 
Okano, H., Ohkubo, C. 2003. Effects of static magnetic fields on plasma levels of 
angiotensin II and aldosterone associated with arterial blood pressure in genetically 
hypertensive rats. Bioelectromagnetics. 24: 403–412. 
 
Okano, H., Ohkubo, C. 2005. Exposure to a moderate intensity static magnetic field 
enhances the hypotensive effect of a calcium channel blocker in spontaneously hypertensive 
rats. Bioelectromagnetics. 26: 611–623. 
 
Pescatello, L., Franklin, B., Fagard, R., Farquhar, W., Kelley, G., Ray, C. 2004. American 
College of Sports Medicine position stand. Exercise and hypertension. Med. Sci. Sports 
Exerc. 36: 533–53. 
 
Philpott, W. 1998. Critical reviews of currently practiced magnetic therapy. 17171 S.E. 29th, 
Choctaw, OK. 88–92. 
 
Plummer, J., Zakaria, A., Ilsley, A., Fronsko, R., Owen, H. 1995. Evaluation of the influence 
of movement on saturation readings from pulse oximeters. Anaesthesia. 50: 423–426. 
 
Ramey, D. 1998. Magnetic and electromagnetic therapy. The Scientific Review of 
Alternative Medicine 1:1-16. 
 
Ratcliffe, P., Eckardt, K., Bauer, C. 1996. Hypoxia, erythropoietin gene expression, and 
erythropoiesis. Handbook of Physiol., Section 4, Oxford University Press. London. 2: 1125–
1153. 
 
Roberts, C. 2004. The effects of magnetic induction of inhaled oxygen on athletic 
performance: A double blind placebo-controlled clinical trial. MPhil. Research Proposal 
MPhil. Sports Med.  University of Cape Town. www.edwafin.co.za/index.php?option 
Roberts, C. 2007. The effects of magnetic induction of inhaled oxygen on athletic 
performance: A double blind placebo-controlled clinical trial. MPhil. Sports Med. University 
of Cape Town  
Roberts, C. Bosch A, Schwellnus, M., 2008. Effects of magnetism, physiological 




Roberts, C., Bosch, A., Schwellnus, M. 2007. Does regular use of a magnetic breathing 
device improve athletic performance? A randomized, placebo-controlled clinical 
trial(Abstract) SA. J. Sports Med. 19(suppl): 33-34.  
 
Ryan, A. 2007. Rest and recovery test on Therahaler O2 Gold [Online]. Available: 
www.edwafin.co.za/TherahalerSports.pdf www.edwafin.co.za/TherahalerSports.pdf 
 
Saini, S., Frankel, R., Stark, D. 1988. Magnetism: a primer and review. AJR Am. J. 
Roentgenol. 150: 735-743. 
 
Sakurai, H., Yasui, H., Kunitomi, K. 2000. Effects of static magnetic fields on dissolved 
oxygen levels in aqueous solutions containing copper(II), iron(II) and heme iron(III) 
complexes. Pathophysiol. 93-99. 
 
Saltin, B., Strange, S. 1992. Maximal oxygen uptake: “old” and “new” arguments for 
cardiovascular limitation. Med. Sci. Sports Exerc. 24: 30-37. 
 
Saltin, B., Henriksson, J., Nygaard, E., Andersen, P. 1977. Fiber types and metabolic 
potentials of skeletal muscles in sedentary men and endurance runners. Ann. N. Y. Acad. Sci. 
301: 3-29. 
 
Shapiro, B. 1973. Clinical application of blood gases. Chicago. Yearbook Med. Publishers. 
30-34. 
 
Sharrard, W. 1990. A double blind trial of pulsed electromagnetic fields for delayed union of 
tibial fractures. Br. J. Bone Joint Surgery. 72B: 347-355. 
 
Sidney, K., Shephard, R. 1977. Maximal and submaximal exercise tests in men and women 
in the seventh, eighth and ninth decades of life. J. Apply. Physiol. 43: 280-287. 
 
Splenger, C., Lenzin, C., Stussi, C., Markov, G., Boutellier, U. 1998. Decreased perceived 
respiratory exertion during exercise and after respiratory endurance training. Am. J. Respir. 
Crit. Care Med. 157: A782. 
 
Splenger, C., Roos, M., Laube, S., Boutellier, U. 1999. Decreased blood lactate 
concentrations after respiratory endurance training. Eur. J. Appl. Physiol. 79: 299-305. 
 
Taylor, H., Buskork, E., Henschel, A. 1955. Maximal oxygen uptake as an objective measure 
of cardiorespiratory function. J. Appl. Physiol. 8: 73-80. 
 
Valbona, C., Hazelwood, C., Gabor, J. 1997. Response of pain to static magnetic fields in 
postpolio patients: A double blind pilot study. Arch. Phys. Med. and Rehabil. 78: 1200-1203. 
 
Van der Linde, M. 2001. Unpublished data. Correspondence: PO Box 2015, Mount 
Edgecombe, South Africa, 4300 
 
Wagner, P. 1996. Determinants of maximal oxygen transport and utilization. Annu. Rev. 
Physiol. 58: 21-50. 
 
Warpeha, J. 2003. Limitation of Maximal Oxygen Consumption: The Holy Grail of Exercise 
Physiology or Fool's Gold? Professionalization of Exercise Physiologyonline. Vol 6(9)  
61 
 
Wognum, B. 2011. Mini review: Erythropoietin (EPO). Catalog #29013, Version 3.0.0. 
 
Zhang, J., Clement, D., Taunton, J. 2000. The efficacy of Farabloc, an electromagnetic 
shield, in attenuating delayed-onset muscle soreness. Clin. J. Sport Med. 10: 15-21. 
 
Zhernovoi, A., Skorik, V., Chirukhin, V., Sharshina, L. 2001. Effect of Stationary Magnetic 
Field on in Vivo Oxygen Binding by Blood. Bull. Exp. Biol. Med. 131: 121-123. 
 
Zweifach, B. 1977. Introduction. In: Kaley G, Altura B, (ed)Microcirculation. Baltimore: 




























PARTICIPANT INFORMATION FORM 
 
 
DIVISION OF HUMAN PHYSIOLOGY 




Ms Robyn Turton, Mr Aroshen Naiker, Dr. Mike Marshall and Professor Edith Peters-Futre from the 
Division of Human Physiology in the School of Laboratory Medicine and Medical Sciences of the 
College of Health Sciences at the University of KwaZulu-Natal would like to conduct the following 
research project:  
 
The efficacy of a Therahaler magnetic breathing device in optimizing cardio-respiratory 
function during a maximal exercise test. 
 
You are being invited to consider participating in this study. 
 
Background to the study: 
Magnetic therapy, the use of magnetic fields to treat a range of medical conditions, has obtained great 
support in recent years. This non-medicinal breathing device is an inhaler containing a magnetic coil 
which is being marketed by Magnetic Air natural health products and has been successfully used in 
improving the oxygenation of blood in asthmatic subjects. Oxygen in the inhaled air passes through 
the magnetic coil in the Therahaler breathing device and acquires a magnetic charge. It is 
hypothesized that the magnetically charged oxygen is more highly attracted to the iron binding sites 
on haemoglobin, thus enhancing the oxyhaemoglobin concentration and oxygen carrying capacity. It 
is suggested that this will enhance O2 uptake and may account for anectodatal reports of improved 
performance in world-class endurance athletes.  
The aim and purpose of this research is to establish whether cardiorespiratory function, maximal 
oxygen uptake and maximal exercise performance during a maximal exercise test is enhanced by the 
use of a 1500G Therahaler. This trial may provide valuable insight into specific physiological 
responses to magnetic fields and inhalation of magnetically charged oxygen. It will also establish 
whether there is scientific verification for the anecdotal claims of endurance athletes that their 
performance and cardio-respiratory function is improved following regular inhalation of magnetically 
charged oxygen. 
 
Who is eligible to participate in this study? 
Male volunteer recreational endurance runners, healthy and relatively well trained,   
 between 18-40 years old 
 completing at least 60 km per week in training during the 3 months prior to the study,  
 are not suffering from any ailment or chronic illness that will impede on the performance 
of the test 
 and do not  
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 use regular medication 
 smoke or consume alcohol excessively 
 have implanted metal or medical devices 
 use any performance enhancing agents 
 
What will be expected from volunteers in this study?  
 You will be asked to: 
1. Use the Therahaler Device 1 and 2 for 28 days between three exercise tests in the laboratory. 
2. Maintain your normal diet and training status throughout the study.  
3.  Provide a small (4ml) venous blood sample before and after each of the maximal exercise tests. 
 
Outline of tests 
As one of 30 healthy male runners who will be required to use the Therahaler Device 1 for 28 days 
after baseline test 1 and then Therahaler Device 2 for 28 days after test 2. This will involve inhaling 
through the little device a minimum of 25 times daily for the 28-day duration of each intervention.  
 
At the start of the study, you will be required to visit the exercise laboratory for a basic 
familiarization session during which vital signs and basic anthropometric and lung function measures 
will be taken, you will be required to fill in a medical and training status questionnaire, and a medical 
doctor will conduct a basic examination of your health status. Thereafter you will be required to 
perform a maximal treadmill exercise test during which heart rate, blood pressure and non-invasive 
oxygen saturation will be measured. Before and after the treadmill tests a small blood sample will be 
taken for analysis of your red blood cell indices. 
 
After using the Therahaler Device 1 and Therahaler Device 2, you will be asked to return to the 
laboratory for a repeat of the maximal exercise tests and provision of small blood samples before and 
after each treadmill test. 
 
How can you benefit from participation in this study?  
Following the study, you will be given the results of each of the laboratory tests and your haematocrit 
and haemoglobin concentrations. The magnetic strength of the two Therahaler devices that you have 
used, will then also be disclosed.   
 
By participating you will establish whether a Therahaler is of benefit to your maximal running 
performance and your lung capacity and function, oxygen carrying capacity and cardiac response to 
exercise.  
 
Will you be exposed to adverse effects of the study? 
A minimal risk factor is involved in any physical test and all necessary precautions will be taken to 
ensure safe conditions.  
 
As you are however a trained athlete, there is only a very slight risk of something unfortunate 
occurring while you are on the treadmill. There is also a very slight risk of complications from 
venipuncture (taking of blood), mainly infection at the site of puncture or inflammation (swelling) of 
the vein used.  
 
In the unlikely event of a complication occurring, Dr. Mike Marshall will be present at all of the 
assessments and taking of the blood samples. He will ensure that procedures are performed according 
to the same standards that you would experience in a hospital environment.  
 
Can you withdraw from the study?  
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As your participation is entirely voluntary, you may withdraw from the study at any time without 
penalty.  
 
Will your individual results remain confidential?  
Yes.  The records identifying the participants will be kept confidential and, to the extent permitted by 
the applicable laws and/or regulations, will not be made publicly available. Although the study is for 





Any out-of-pocket expenses which you may incur as a result of your participation in this study (e.g. 
traveling expenses) will also be reimbursed by the research team. 
 
Further queries 
Should you have any queries or wish to obtain further details regarding this study, please do not 
hesitate to contact the following persons at the University of Kwa-Zulu-Natal: 
Mr. Aroshen Naiker – 083-618 3478 
Miss Robyn Turton_ 084-606-6987             
Prof. Edith Peters-Futre - (031) 260 4237 (W); 0737597974 
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 






SUBJECT CONSENT FORM 
 
 
DIVISION OF HUMAN PHYSIOLOGY 
COLLEGE OF HEALTH SCIENCES 
 
THE EFFICACY OF A 1500G THERAHALER MAGNETIC BEATHING DEVICE IN 
OPTIMIZING CARDIO-RESPIRATORY FUNCTION DURING A MAXIMAL EXERCISE 
TEST. 
 
I, ………………………………………….. hereby agree to participate in a research study to be 
performed by Ms Robyn Turton, Mr Aroshen Naiker, Professor Edith Peters-Futre and Dr. Mike 
Marshall in the Division of Human Physiology in the College of Health Sciences of the University of 
KwaZulu-Natal. I have been informed about the study by the principal investigator, Mr. Muhammad 
Vahed. 
 
I understand that the basic procedures to be carried out are to include:  
 
1. Use of the Therahaler magnetic breathing device for 28 days after the first laboratory test and 
28 days after the second laboratory test. 
 
2. Completion of three maximal exercise tests on a treadmill. 
 
3. Completion of a brief medical and training questionnaire before the trial and provision of 
2ml blood samples before and after the treadmill tests. 
 
The details of these procedures have been explained to me in full. I am aware that a certain level of 
discomfort may occur when the blood is taken and that this procedure may be accompanied by 
certain medical risks including infection and inflammation of the vein.    
 
I understand that this study will form part of the Masters Degree of Ms. Robyn Turton and that the 
results may be published.  
 
I understand that participation is entirely voluntary and that I may withdraw from the study at any 
time. 
 
I may contact the principal investigator of the project, Ms Robyn Turton, Mr Aroshen Naiker at 
0737861269 at any time if I have questions about the research or if I am injured as a result of the 
research. 
 
______________________________            ____________________ 
Signature of Participant                       Date 
 
______________________________            ____________________ 







                           
DIVISION OF HUMAN PHYSIOLOGY 
COLLEGE OF HEALTH SCIENCES                
                                         
The efficacy of a 1500G Therahaler magnetic breathing device in optimizing cardio-respiratory 
function during a maximal exercise test. 
 
1. Name…………………………………     2. Date of birth………………………………… 
 
3. Are you currently in good health? (i.e. No illness within the last 3 months)     
yes □ no □.  If no, please specify 
 ………………………………………………………………………………………………… 
 
4. Do you suffer from any chronic medical conditions?  (conditions diagnosed  more than 3 months 
ago which affect your everyday life) e.g. diabetes, high blood pressure, asthma.  
yes □ no □.  If yes, please list 
………...……………………………………………………………………………………….. 
 
5. Do you use anti-inflammatory tablets during a race of this nature?   
yes □ no □. If yes, please specify the type and dosage 
…………………………………………………………………………………………………. 
 
6. Are you using any other medication?  
yes □ no□.  If yes, please list 
…………………………………………………………………………………………………. 
 
7. Do you suffer from a bleeding disorder e.g. haemophilia?  
yes □ no □  If yes, please specify 
…………………………………………………………………………………………………. 
 
8. Have you been admitted to hospital within the last year?   
yes □ no □  If yes, please specify 
…………………………………………………………………………………………………. 
 
9. Do you smoke?  yes □ no □  
If yes, please specify amount per day and for how many years 
…………………………………………………………………………………………………. 
 
10. Are you presently or have you ever used performance enhancing drugs? (e.g. Erythropoeitin, 
anabolic steroids)    
yes □ no □.  If yes, please list 
…………………………………………………………………………………………………. 
 
11. Do you have a cardiac pacemaker or any other implanted electromedical device?  











DIVISION OF HUMAN PHYSIOLOGY 
COLLEGE OF HEALTH SCIENCE 
 
 The efficacy of a 1500G Therahaler magnetic breathing device in optimizing cardio-
respiratory function during a maximal exercise test. 
 
Name……..…………………………………………………………………………………… 
Device code (to be filled in by researchers)…………………............................................           
    
SECTION A: PLEASE ANSWER ALL QUESTIONS.   
 
1.  Date of birth: …………………………………        Age: …………………………..........    
2.  Address: …………………………………………………………………………………… 
3.  Telephone numbers:   Home: ……………………………………………………….. 
Work: ………………………………………………………... 
Cell: ………………………………………………………….. 
4. Running club: ………………………………………………………………………………. 
5. Occupation: ……………………………………………………………………………….... 
 
Please tick one of the boxes in each of the following questions:  
 

















9. Running history:   Serious\social: ………………………………………………. 
             Age started running: ……………………………..…….years 
Level of training during these years: ………………………. 
Total number of running  races: …………………………… 
□ <  5 
□ 6 - 10 
□ 11 - 15 
□ 16 – 20 
 
□ WEEK-END WARRIOR (only run on weekends) 
□ SERIOUS AMATEUR (> 5 races per year) 
□ ELITE (regular top 10% finisher) 
□ PROFESSIONAL (paid to run) 
□ OTHER – SPECIFY…………………………. 
□ FUN RUNS 
□ < 5  x 21 km races)  PER YEAR 
□ < 5 marathons (42km)  PER YEAR 
□ > 2 ultra marathons (52 km or longer) PER YEAR 
□ PREVIOUS MULTISTAGE RACES e.g. Cape Odyssey, 3 Cranes 





10.  Sports played in last 12 months (squash, rugby, soccer, etc)              
…………………………………………………………………………………………............ 
Dietary and fluid intake details 
 
1. Are you on any specific diet? (Vegetarian, fish only, etc)  
 
…………………………………………………………………………………………………. 
2. Are you presently using any supplements? (Multivit, Calmag, etc)  
yes  no .  If yes, please specify how much you are taking and how often: 
…………………………………………………………………………………………………. 
3.  Do you use water and/or a sports drink during training?……………………………….... 








______________________________            ____________________ 
Participant’s Signature    Date 
 
 
______________________________             ____________________ 

















     
      
NAME 
     
DEVICE CODE   
    





TRAINING SCHEDULE HAVE YOU TAKEN ALL 
SUPPLEMENTS/CURRENT 






        
06/27/13 
 
        
06/28/13 
 
        
06/29/13 
 
        
06/30/13 
 
        
07/01/13 
 
        
07/02/13 
 
        
07/03/13 
 
        
07/04/13 
 
        
07/05/13 
 
        
07/06/13 
 
        
07/07/13 
 
        
07/08/13 
 
        
07/09/13 
 
        
07/10/13 
 
        
07/11/13 
 
        
07/12/13 
 
        
07/13/13 
 
        
07/14/13 
 
        
07/15/13 
 
        
07/16/13 
 









        
   
Time Fraction 













   
          
ACTIVE 
1 6.85 2.00 2.00 2.85 6.00 
   2 6.00 2.50 1.00 2.50 6.00 
   3 7.22 3.00 1.70 2.52 7.00 
   4 4.57 0.00 1.00 3.57 6.00 
    +3 
DAYS 2.91 0.91 1.00 1.00 3.00 
   
  











   
9.50 3.03 3.51 
    
   
16.03 
 
       
          
PLACEBO 
5 6.11 2.00 2.00 2.11 6.00 
   6 6.17 1.84 1.40 2.93 6.00 
   7 5.00 2.50 1.50 1.00 5.00 
    +3 
DAYS 1.34 0.67 0.00 0.67 2.00 
   
  











   
10.22 2.86 2.45 
    
   
15.53 
 






AN EXAMPLE (PARTICIPANT EXCLUDED) 
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Thank you very much for agreeing to take part in the above study. We are pleased to be able to 
provide you with the following feedback: 
Uncoding of the devices has revealed that you were on an inactive placebo device for the first 4 week 
period; thereafter you were on an active device containing a 1500g magnet for the following 4 weeks. 
 






(POST Device 2) 
Predicted norm for active 
athlete of your age, 
gender and 
BMI/researcher’s comment 
Age 28 - 
Medication General vitamin   
Sporting Discipline Running, Paddling, Diving  
Height (m) 1.71  
Cardiovascular status Normal rhythm, heart sounds with no murmurs noted 
Respiratory status No abnormalities detected  
Dermatological No abnormalities/ dermatological lesions noted 
Musculoskeletal No pain or limitation on range of motion of weight bearing joints 
Mass (kg) 65.6 67.3 Gained  1.7, 1.12% gain 
BMI 22.4 23 Normal range:18.5-24.9 
Triceps skinfold (mm) 5.8 5.4  
Chest Skinfold (mm) 4.6 4.9  
Midaxilla (mm) 4.8 5.4  
Subscapular(mm) 8.7 8.8  
Suprailliac(mm) 6.2 6.5  
Abdominal (mm) 6.3 6.2  
Thigh (mm) 9.3 7.8  
Body Fat % (determined from 
above skinfolds) 
6.1 6.0 
Elite Triathletes average 
between 5 and 12% 
WAIST circumference (cm) 71 73 >95cm = central obesity  
Hip Circumference( cm) 88 88  
Waist : Hip Ratio 0.81 0.83 < 0.90 =low risk 
Resting Pulse Rate (bpm) 58 52  
THE EFFICACY OF A THERAHALER MAGNETIC BREATING DEVICE IN 
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Resting Blood Pressure 
(mmHg) 
               Systolic 











Within healthy range 
Reported Compliance in using Device: 
Compliance with the use of the first inactive device did not reach the requirements of 30 inhalations 
per day. It was reported in your training diary that during this first period you used the device an 
average of 15-20 times per day. During the second period of the trial compliance with use of the 
device increased considerably to meet the studies requirements of 30 inhalations per day. 
 
Training Status during the Experimental Period: 
This was a very important confounder in the study which will affect the internal validity of the 
results. You were asked to keep your training status constant. 
 
While using Active Device: 
During this period of the trail you reported that you were decreasing your running mileage in order to 
focus on strength training on the water and gym. However you retained a consistent daily training 
status throughout this period  
 
While using Placebo Device: 
A consistent daily training status was reported during this first period of the trial. You did however 
report that during this time you were doing more running than when you moved onto the active 
device.  
 
Other possible Confounders: 
Illness: Nil 
Use of medication: Nil 
Use of performance enhancing agents: 
USN carbohydrate racing juice 
 
TABLE 2: Lung Function 








NORMS for inactive 
person of your 
















Sec ( FEV1) 
L/min 4.46 4.5 4.44 4.15 
FVC/FEV1 
ratio 
% 0.83 0.81 0.81 
>0.80 : no obstruction 





L/min 5.57 5.62 5.64 5.05 
Breath 
holding Time 











TABLE 3: Performance in maximal running test 











Body Mass kg 65.6 67.3 67.3 
Body mass gain, a 
confounder 
 




bpm 167 153 156 




% 96 94 96  
 














Training /learning effect 
after initial baseline 
test? Max Running 
Time 
min: sec 11:00 12:00 12:03 
Heart Rate bpm 194 191 195  




9 10 10  
VE (Minute 
ventilation) 
L/min 136 152 153  
Tidal volume L 2.6 2.8 2.8  
Breathing 
frequency 
b/min 53 56 54  
O2consumption 
(VO2) 
L/min 5144 5164 5489 
Max achieved after 
placebo trial when you 
were doing more 
running. Outstanding 
capacity! 








1.04 1.10 1.08 
Greatest reliance on  
CHO breakdown & 
tolerance of “anaerobic” 





Heart rate: 60 sec 
post 
bpm 162 162 153 Greater endurance as 
tests progressed over the 
8 weeks 
Heart rate: 120 
sec post 
bpm 128 122 125 
Diastolic Blood mmHg 58 58 54 Drop indicates dilation 
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Pressure of blood vessels in 
response to intense 
exercise 
 
TABLE 4: Results of Full Blood Count 
 Units Baseline 
After use of 
Device 1 




Red Blood Cell Indices 
Hemoglobin(Hb) g/dL 15.6 15.6 15.0 13.0-17.0 
Red Blood Cell 
count (RBC) 
1012 /L 5.03 5.0 4.77 4.5-5.5 
Hematocrit(Hct) % 45.8 45.5 43.3 40-50% 
White Blood Cell Indices 
White Blood Cell 
Count (WBC) 
109 /L  6.51  3.92-9.88 
Neutrophills 109 /L  3.07  2.0-7.5 
Lymphocytes 109 /L  2.65  1.0-4.0 
Monocytes 109 /L  0.27  0.18-1.0 
Eosinophils 109 /L  0.35  0-0.45 
Basophils 109 /L  0.02  0-0.2 
Platelets 
Platelets 109 /L  239  150-450 
 
Conclusion: 
You have an outstanding O2 carrying and uptake capacity which is supported by your high red cell 
status in your blood and a good maximum ventilatory capacity. It is really a great pity that you 
changed over to doing less running and more strength training while on the active device. But this 
does show that there is no replacement for muscle specific training. To achieve max on the treadmill, 
you need to do running training; it improves capillarisation and oxidative capacity in the trained leg 
muscles, which are important determinants of VO2 max when it is measured during treadmill 
running.  
 
As the change in mode of training was a major confounder, the findings of this trial can unfortunately 
not be used to reveal how effective the magnetic device is for you. 
 




Masters Student in Sports Medicine 
Aroshen Naicker 
Honours student in Exercise Physiology 
Dr Mike Marshall 
Consulting Physician  
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THE EFFICACY OF A THERAHALER MAGNETIC BREATING DEVICE IN OPTIMIZING 
CARDIO-RESPIRATORY 
 
Dear ……..   
 
Thank you very much for agreeing to take part in the above study. We are pleased to be 
able to provide you with the following feedback: 
 
Uncoding of the devices has revealed that you were on an active device containing a 1500g 
magnet for the first 4 week period; thereafter you were on an inactive placebo device for the 
following 4 weeks 
 








Predicted norm for active 
athlete of your age, 
gender and BMI/researcher’s 
comment 
Age 29 Years 
Medication None reported 
Sporting Discipline Hockey, elite trail runner and Mountain Biking 
Height (cm) 183 
Cardiovascular status Normal rhythm, heart sounds with no murmurs noted 
Respiratory status No abnormalities detected 
Dermatological No abnormalities/ dermatological lesions noted 
Musculoskeletal 
No musculoskeletal problems which will interfere with 
performance in treadmill running test or training 
Mass (kg) 72 71.6 Minimal loss 
BMI 21.5 21.4 
In lower section of normal 
range (18.5-24.9) despite 
added weight of muscle. 
Triceps skinfold (mm) 7.3 8.4  
Chest Skinfold (mm) 6.9 5.3  
Midaxilla (mm) 6.2 6.3  
Subscapular(mm) 11.5 9.8  
Suprailliac(mm) 8.4 8.2  
Abdominal (mm) 8.3 8.0  
Thigh (mm) 7.1 7.4  
Body Fat % (determined 
from above skinfolds) 
7.84 7.47 
6-15% for elite cyclists; 5-12% 
for elite triathletes 
WAIST circumference (cm) 72 74 >94cm = central obesity 
Hip Circumference( cm) 88 93  
Waist : Hip Ratio 0.82 0.80 
< 0.90 =low risk 
 
Resting Pulse Rate (bpm) 49 40 
Excellent! As expected for elite 
endurance athlete 










               Systolic 





Within healthy range 
Reported Compliance in using Device: 
The use of your initial active device was compliant with that of the studies requirements, 
averaging 30 inhalations every single day. During the use of the second (inactive) device 
compliance dropped a little as there were a few days on which less inhalations were 
reported. 
 
Training Status during the Experimental Period: 
This was a very important confounder in the study which will affect the internal validity of the 
results. You were asked to keep your training status constant. 
 
While using Active Device: 
A very consistent training history was reported throughout both trials. The mileage 
accumulated was also consistent at approximately 60km/wk. There is a range in distances 
between 10 and 20km of running per day, with a few rest days taken. The intensity of the 
exercise also remained consistent throughout the trial. 
 
While using Placebo Device: 
As above, a consistent training diary throughout the 8 weeks. 
 
Other possible Confounders: 
Illness: None reported 
Use of medication: None reported 
Use of performance enhancing agents: None reported 
 
TABLE 2: Lung Function 


















L/min 4.86 4.94 5.33 5.84 






Sec ( FEV1) 
L/min 4.12 4.18 TD 4.75 
FVC/FEV1 
ratio 
% 0.85 0.85 TD 0.80 
>0.80 absence 






L/min 4.76 5.08 5.07 5.84 
Also appears 











L/min 158 166 160  
This places you 
into the elite 
category 








TABLE 3: Performance in maximal running test 
 













Body Mass kg 72.0 73.0 71.6  
 




bpm 160 152 152 




% 92 98 93 
Far less of a drop in 
oxygen saturation of 
haemoglobin after 
being on active device 
 
















min: sec 12:00 12:00 12:04  
Heart Rate bpm 193 186 187 
Lower HR max  
compared to baseline, 
but little difference after 
use of the two devices 




9 9 9 




L/min 158 166 160 
Greatest after use of 
active device 
Tv( Tidal Volume) L 2.99 3.01 2.98 
Rf( respiratory 
Frequency) 




ml/min 5378 5728 5760 
Improved VO2max 
compared to baseline; 
excellent result! Active 
device usage did 
however not appear to 
improve this capacity. 








1.14 1.09 1.01 
Reduced reliance on 
oxygen independent 
metabolism with time, 












recovery: 60 sec 
post 
bpm 147 138 134 
Improved heart rate 
recovery. This again 
points to improved 
endurance status with 
time 
Heart rate: 120 
sec post 
bpm 122 112 107 
Diastolic Blood 
Pressure 
mmHg 72 70 60 
Dilation of blood 
vessels in response to 
intense exercise 
improved with time ( 
and fitness) 
 
TABLE 4: Results of Full Blood Count 
 








Red Blood Cell Indices 
Hemoglobin(Hb) g/dL 16 15.8 15.6 13.0-17.0 
Red Blood Cell 
count (RBC) 
1012 /L 4.92 4.73 4.61 4.5-5.5 
Hematocrit(Hct) % 47.4 45.7 44.5 40-50% 
White Blood Cell Indices 
White Blood Cell 
Count (WBC) 
109 /L 6.23 6.19 5.43 3.92-9.88 
Neutrophills 109 /L 3.23 3.13 2.77 2.0-7.5 
Lymphocytes 109 /L 2.22 2.22 1.92 1.0-4.0 
Monocytes 109 /L 0.36 0.34 0.36 0.18-1.0 
Eosinophils 109 /L 0.27 0.36 0.27 0-0.45 
Basophils 109 /L 0.02 0,03 0.02 0-0.2 
Platelets 




Congratulations on an outstanding VO2 max! This places you into world class category! 
 
Although you report that training status was constant, endurance levels do appear to have 
improved over the course of the study. This is particularly reflected in your heart rate 
recovery, lower RER, and greater vasodilatation (lower DBP) during the post-placebo 
device trial. 
 
Red Blood indices remained relatively constant. We shall however be investigating your 
hydration status on test days to ensure that this remained constant. 
 
Your WBC counts appear to have been depressed following the placebo trial. Reasons for 
this could include suppressed immune defences following overtraining or high levels of 




 In summary, the use of the active magnet device did not appear to be beneficial to you in 
terms of enhancing your performance at endurance events. 
 
Robyn Turton 
Masters Student in Sports Medicine 
 
Aroshen Naicker 
Post Grad student in Exercise Physiology 
 
Dr Mike Marshall                                                         
Consulting Physician  
                                                                                     
                                                                                    Prof Peters-Futre 
                                                                                    Research Supervisor 
 
 
 
 
 
 
 
 
 
 
 
 
 
